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ABSTRACT 
 
Anxiety disorder is a debilitating condition that affects up to 10% of the adult population in the 
world. Mapping of brain activity in patients and in mouse models has shown that anxiety- related 
behavior is associated with abnormally high firing of basal amygdala and its downstream target 
nucleus, the centromedial amygdala. A plausible mechanism for this increased excitatory drive is 
dysfunction of amygdala inhibitory synapses, but the proteins that contribute to such dysfunction 
and that may serve as novel targets for pharmaceutical intervention are largely unknown. Here, I 
investigate the function of two synaptic adhesion proteins implicated in neuropsychiatric disorders, 
Neuroligin 2 (Nlgn2) and IgSF9b, at inhibitory synapses in the anxiety- processing circuitry in 
amygdala. Using a combination of behavioral assessment, quantitative morphological analysis, 
cFOS induction assay, anatomical tracing and in vivo and in vitro electrophysiology, I show that 
deletion of Nlgn2 causes a prominent anxiety phenotype and results in upregulation of activity of 
excitatory projection neurons in basal amygdala, which in turn robustly enhance the firing of 
centromedial amygdala under anxiogenic conditions. To identify additional inhibitory synaptic 
proteins involved in anxiety regulation, I investigated the function of IgSF9b, a novel cell adhesion 
molecule that interacts with Nlgn2 in vitro and hence potentially modulates the anxiety phenotype 
of Nlgn2 KO mice. I show that in sharp contrast to Nlgn2 KO mice, deletion of IgSF9b decreases 
anxiety behavior and enhances the activation of inhibitory interneurons in basal amygdala under 
anxiogenic conditions. Moreover, deletion of each protein affects distinct subsets of inhibitory 
synapses in basal and centromedial amygdala. Strikingly, those differential mechanisms interact 
in mice lacking both proteins to completely rescue anxiety phenotype by normalizing the anxiety- 
associated firing of centromedial amygdala. Specifically, deletion of IgSF9b rescues the 
enhancement of high gamma (70-120 Hz) band activity of centromedial amygdala in Nlgn2 KO 
mice during exposure to anxiogenic conditions.  My findings indicate that Nlgn2 and IgSF9b play 
a crucial role in anxiety processing, thus providing important insights into the molecular 
mechanisms of anxiety and into potential drug targets for anxiety treatment. 
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1. INTRODUCTION 
 
Searching for the Molecular Basis of Anxiety 
 
Survival of an organism is crucially dependent on the ability of its brain to generate a precise 
behavioral response to threats. A complex neural network continuously categorizes multimodal 
environmental cues as safe or threating and, upon detecting a threating stimulus, commands the 
brainstem centers of motor and autonomic function to prepare the body for escape or fight. 
Dysfunction of this neural processing may give rise to excessive defensive behavior on the expense 
of other vital behaviors such as food seeking and mating, thus reducing the chances of survival.  
 
In humans, avoidance of daily activities due to over apprehension of possible threats is the core 
symptom of anxiety disorder (LeDoux et al. 2017). Anxiety disorder is among the most common 
psychiatric disorders, with life time prevalence of ~ 30 %  in adults (Kessler et al. 2005). Studies 
of underlying mechanisms showed that anxiety patients have an enhanced activity of brain regions 
involved in processing of threat- related stimuli, which henceforth will be referred to as “anxiety- 
related processing”, and display abnormally low extracellular levels of the inhibitory 
neurotransmitter Aminobutyric Acid (GABA) (Petty & Sherman 1984; Etkin & Wager 2007). 
Collectively, these findings indicate that decreased GABAergic neurotransmission in the anxiety 
processing brain regions is one of the key mechanisms of anxiety. Therefore, identifying the 
molecular factors that govern GABAergic neurotransmission across the anxiety processing 
circuitry is essential to understanding the molecular basis of anxiety.  
 
1.1 Brain Regions in Anxiety  
In the center of anxiety- related processing network lies the amygdaloid complex, a multinuclear 
structure located within medial temporal lobe. Amygdala nuclei regulate a wide range of 
behavioral responses to emotionally significant stimuli, such as food or threat. The deficits in 
emotional regulation following amygdala lesioning was demonstrated in monkeys, rodents, and, 
importantly, in humans, indicating that the function of amygdala is conserved across species 
(Weiskrantz 1956; Blanchard & Blanchard 1972; Anderson & Phelps 2001; Janak & Tye 2015). 
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Investigation of the functional role of amygdala nuclei identified two nuclear complexes as key 
regions in the acquisition, storage and expression of conditioned fear: the basolateral complex and 
the central nucleus (LeDoux 2003, Figure 1.1). The basolateral complex (BLA) receives sensory 
information from thalamus, cortical association areas and prefrontal cortex through its lateral 
nucleus (LA), processes this information in the basal nucleus (BA) and sends it to the central 
nucleus (CeA). CeA (specifically centromedial nucleus CeM) in turn projects to hypothalamus and 
brainstem to generate a behavioral output (Romanski et al. 1993; Sah et al. 2003). This serial 
processing of information (Figure 1.2) provides a useful platform to study the effect of genetic, 
pharmacological and functional manipulations of individual BLA nuclei on fear- related behavior. 
 
 
Figure 1.1| Serial processing of sensory information in BLA-CeA circuit.  
Coronal section of BLA and CeA, with outlined lateral, basal, centrolateral and centromedial nuclei (left) 
and scheme of overall flow of sensory information across BLA- CeA circuit (right). CeM- centromedial 
nucleus.  ITC- complex of GABAergic neurons that are involved in regulation of fear- related behavior. 
Adapted from Sah et al. 2003; Ehrlich et al. 2009. 
 
Substantially less is known about the role of the BLA- CeA complex in the regulation of anxiety- 
related behavior, although it is generally assumed that the circuity must at least partially overlap 
with the fear- processing circuitry (Tovote et al. 2015). Optogenetical stimulation of excitatory 
projections from BA to the lateral part of central nucleus (CeL) in mice decreases the avoidance 
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of an exposed arena during an assay of anxiety (Tye et al. 2011). Moreover, activation of neurons 
projecting from the BA to the medial part of central nucleus (CeM) increases avoidance behavior 
in mice (Namburi et al. 2015). Since disrupted BA- CeM functional connectivity was found in 
patients with generalized anxiety disorder (Etkin et al. 2009), these findings support the key role 
of BLA projections to CeM in anxiety.    
 
In addition to its intra-amygdalar interactions, BLA is part of a brain-wide anxiety-processing 
network (Figure 1.2). Medial prefrontal cortex (mPFC) sends a robust excitatory projection to 
BLA, which synapses onto inhibitory neurons and supresses BLA output to reduce fear expression 
in the absence of threat (Mcdonald et al. 1996; Sotres-Bayon et al. 2004; Likhtik et al. 2013). 
Additionally, BLA is reciprocally connected with ventral hippocampus (vHPC), and activation of 
BLA axon terminals was shown to excite hippocampal neurons and enhance avoidance behavior 
(Pikkarainen et al. 1999; Felix-Ortiz et al. 2013). The role of BLA long range connectivity in 
mediating anxiety- related behavior was recently demonstrated in vivo by showing that 
synchronized activity across the mPFC-vHPC- BLA circuit at specific frequency ranges encodes 
safe and danger zones during exploration of an open arena (Stujenske et al. 2014). The neural 
correlate of safety and danger encoding in CeM however remains unexplored.  
 
 
Figure 1.2| BLA long-range connections in regulation of diverse behavioral domains.  
BLA regulates anxiety through excitation of vHPC and inhibition of Bed Nucleus of Stria Terminalis 
(BNST) and CeL. More functional BLA connections were described so far for fear- related behavior (here: 
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freezing, reinstatement and reinforcement) than for anxiety. AC, auditory cortex; adBNST, anterodorsal 
bed nucleus of the stria terminalis; EC, entorhinal cortex; Hyp, hypothalamus; IL, infralimbic cortex; MGN, 
medial geniculate nucleus; mPFC, medial prefrontal cortex; NAc, nucleus accumbens; ovBNST, oval 
nucleus of the BNST; PBN, parabrachial nucleus; PL, prelimbic cortex; vHPC, ventral hippocampus. 
Adapted from Janak & Tye 2015.  
 
1.2 Inhibitory Regulation of Anxiety 
 
The excitatory output of BA is tightly regulated by GABAergic interneurons, which determine the 
spiking rate and coordinate the stimulus-specific activation of BA projection neurons. Interneurons 
comprise 20% of neuronal population in BA and form local inhibitory circuits that provide feed 
forward and feedback inhibition to BA projection neurons (Spampanato et al. 2011). There are at 
least 4 populations of interneurons, that can be distinguished by expression of calcium binding 
proteins, as well as by their postsynaptic targets: 1) Parvalbumin+/Calbindin+; 2) 
Somatostatin+/Calbindin+; 3) VIP+/Cholecystokinin+/Calretinin+; 4) Cholecystokinin+  
(Kemppainen & Pitkanen 2000; Muller et al. 2007; Muller et al. 2006; Spampanato et al. 2011; 
summarized in table 1.1). This anatomical heterogeneity underlies the functional heterogeneity of 
BA interneuron populations.  
 
Table 1.1| Characteristics and function of interneurons in BA 
 
Post synaptic targets Anxiety- related function*
General Specific
Calbindin (CB) Parvalbumin (PV) Somata,  axon initial 
segment, proximal 
dendrites
Perisomatic inhibition of 
1 
projectors to CeM
Somatostatin (SOM) Distall dendrites Dendritic disinhibition of 
1 
projectors to CeM
Cholecystokynin       
(CCK)**
Somata, proximal 
dendrites
Perisomatic inhibition of 
2 
projectors to mPFC
Neuronal markers
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1. Wolff et al. 2014  2.Vogel et al. 2016b 
* Contribution to expression of fear- related behavior 
** Subpopulation of CCK neurons additionally expresses calretinin 
 
The role of each class of inhibitory interneurons in regulation of the excitatory output of BA was 
studied mainly in the context of fear- related behavior using fear conditioning paradigm, during 
which an animal learns to associate neutral sensory stimulus with electric shock. Parvalbumin+ 
interneurons were shown to distinctly respond to “neutral” (auditory tone) or “negative” (foot 
shock) sensory stimuli, demonstrating that BA interneurons may encode the stimulus valence 
(neutral vs negative). During different stages of fear conditioning Parvalbumin+ interneurons either 
directly inhibited or indirectly disinhibited principal neurons by inhibiting Somatostatin+ 
interneurons, enhancing the association between foot shock and auditory tone and consequently, 
the fear response (Wolff et al. 2014).  This work identified that Parvalbumin+ - Somatostatin+ - 
projection neuron microcircuit in BA (Figure 1.3) is crucial for shaping a behavioral response to 
fear. Similarly, Cholecystokinin+ interneurons form microcircuits with projection neurons 
targeting fear- regulating region in mPFC  to modulate fear- related behavior (Vogel et al. 2016b). 
These studies establish the inhibitory network in BA as a regulator of stimulus- specific behavioral 
outputs in fear- related processing.  
 
Figure 1.3| Microcircuit in BA that mediates fear- related behavior. Parvalbumin+ interneurons form 
synapses on the soma and Somatostatin+ interneurons form synapses on the dendrites of BA excitatory 
pyramidal- like neuron that projects to down stream regions. Adapted from  Südhof 2008. 
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In stark contrast to cortical like- BA, CeM neurons have the same origin as striatal neurons and 
are predominantly GABAergic medium spiny projection neurons (Schiess et al. 1999). Very little 
is known about the expression of neuronal markers in CeM, which is under inhibitory control of 
CeL (specifically of CeL interneurons that express marker PKC) but it is thought not to have local 
inhibitory circuits of its own (Ciocchi et al. 2010). Since CeM is a main region that translates BA 
inputs into fear response, a detailed analysis of both BA and CeM inhibitory regulation is essential 
for understanding the neural mechanisms underlying anxiety- related behavior. 
 
1.3 Molecular Regulation of Anxiety  
 
The function of inhibitory network in BA is mediated through GABA. BA has one of the highest 
concentrations of GABAA receptors in the brain, especially in the anterior part of BA (Niehoff & 
Kuhar 1983).  GABAA receptors mediate fast synaptic inhibitory transmission in BA (Sanders & 
Shekhar 1995), and blocking their activity produces behavioral and autonomic manifestations of 
anxiety such as avoidance behavior, fight or flight response, increase in heart rate and blood 
pressure (Sanders & Shekhar 1991; Sanders & Shekhar 1995). The key role of GABA receptors 
in regulating anxiety- related processing in BA is further supported by widespread usage of 
benzodiazepines, pharmaceutical agents that enhance the affinity of GABA receptors to GABA, 
to alleviate anxiety in patients with anxiety related disorders (Smith 2001). It suggests that 
dysfunction of BA GABAA receptors may be one of the major molecular mechanisms underlying 
decreased inhibitory tone in BA in anxiety disorders. 
 
The contribution of chronic GABAergic dysfunction in BA to anxiety disorders is demonstrated 
in a mouse model of anxiety that lacks GABA synthetizing enzyme Glutamate Decarboxylase 65 
(GAD 65). GAD 65 KO mice show an increase in anxiety- related behaviours, that is accompanied 
by decreased inhibitory drive in some amygdala regions (Lange et al. 2014; Müller et al. 2015). 
Additionally, mice lacking Fmr1 protein have reduced synaptic GABA in BA. Mutations in Fmr1  
are linked to Fragile X syndrome in humans, one of manifestations of which is anxiety (Olmos-
Serrano et al. 2010). These studies suggest that dysfunction of inhibitory synapses in BA may be 
a common pathophysiological pathway underlying anxiety in mouse models of neuropsychiatric 
disorders. Thus, understanding the molecular mechanisms that govern inhibitory synaptic function 
in BA may provide an insight into molecular mechanism underlying anxiety related disorders.     
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1.4 Molecular Components of Inhibitory Synapses  
 
Fast synaptic inhibitory transmission in the central nervous system is mediated through signalling 
between highly specialized pre- and postsynaptic compartments that tightly regulate the frequency 
of action potentials produced by neurons and are therefore critical to all the aspects of brain 
function. Two major postsynaptic factors determine the efficiency of signalling at the inhibitory 
synapse: the conductance of GABA binding ionic channels (GABAA receptors) and the number of 
GABAA receptors at the synaptic sites. The functional properties of GABAA receptors are 
determined by their subunit composition, and their precise subcellular localization is achieved via 
coordinated action of scaffold proteins and adhesion proteins at postsynaptic sites. Loss of any part 
of this machinery has a severe impact on GABAergic function (Fritschy et al. 2012). 
 
1.4.1 Structure and Function of GABAA receptors 
 
GABAA receptors are transmembrane ionic channels which, upon binding of extracellular GABA, 
allow the hyperpolarization of the membrane via influx of chloride ions into the neuron. Each 
channel consists of a pentameric combination formed out of 15 subunits 
(with the most common subunit composition consisting of two  subunits 
(generally or 3), two  subunits and a 2 subunit (Macdonald & Olsen 1994; Whiting et al. 
1999). GABAA receptors show high molecular and functional heterogeneity across brain regions 
and cellular compartments (Fritschy & Mohler 1995),  but the role of individual GABAA subunits 
in receptor function remains largely unknown.   
 
A detailed study of expression and function of different GABA receptor subunits in BA and CeA 
revealed that and subunits are highly expressed in BA. Interestingly, subunit is 
absent andsubunit is expressed at a low level inCeA, suggesting that inhibitory transmission 
in BA and CeA is mediated through different sub types of GABAA receptors. Activation of both 
andsubunits, and to a lesser extent subunit of GABAA receptors increases inhibitory 
synaptic input on pyramidal neurons in BA (Marowsky et al. 2004No postsynaptic inhibitory 
currents mediated by other types of inhibitory receptors, such as glycine, GABAB and GABAC 
receptors were detected in basal amygdala (Sanders & Shekhar 1995; Marowsky et al. 2004). 
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Taken together, these studies indicate that inhibitory transmission within basal amygdala circuits 
is predominantly mediated by GABAA receptors that contain andsubunits. 
 
Several studies have investigated the physiological function of different GABAA receptor subunits 
using a KO approach of individual subunits in vivo. These studies demonstrated that GABAr2 
KO mice die shortly after birth due to severe reduction in channel conductance and reduced 
postsynaptic clustering of GABAA receptors, revealing the pivotal role of 2 subunit in GABAergic 
transmission (Günther et al. 1995; Essrich et al. 1998). In contrast, deletion of 1 subunit is not 
lethal and does not lead to severe behavioral phenotypes, although it causes loss of ~ 60% percent 
of GABAA receptors in cerebral cortex (Kralic et al. 2002), suggesting that 1 may be at least 
partially functionally redundant. These and additional studies emphasized that the mechanisms 
that determine the composition of GABAA receptors are crucial for inhibitory function. These 
mechanisms most likely involve interactions with scaffold and adhesion proteins that may bind 
specific GABAA receptor subunits at the post synapse (Fritschy et al. 2012).  
 
1.4.2 Scaffold Proteins of Inhibitory Synapses 
 
Scaffold proteins are cytosolic proteins that attach to the cytoskeleton in proximity of post synaptic 
membrane and form multimeric complexes that serve as aggregating platforms for various 
components of post synaptic density (Sheng 1996). The major scaffold protein of inhibitory 
synapses is gephyrin.  Gephyrin forms hexagonal lattice underneath the postsynaptic membrane 
and aggregates GABAA and glycine receptors upon their insertion into the postsynaptic membrane 
via multiple binding sites. During synapse formation, gephyrin is recruited to the postsynaptic 
membrane via interaction with the GDP/GTP exchange factor collybistin, which anchors gephyrin 
to the membrane by binding both gephyrin and membrane lipids ( Betz et al. 2000; Poulopoulos 
et al. 2009).  Apart from driving the clustering of synaptic GABA receptors, gephyrin binds the 
synaptic adhesion protein Nlgn2, thus indirectly contributing to stabilization of the synaptic 
structure (see below). The crucial role of gephyrin in synaptic transmission is demonstrated by the 
lethality of gephyrin KO mice. (Feng et al. 1998) and by dramatic reduction of synaptic GABA 
receptors and the amplitudes of postsynaptic inhibitory currents in gephyrin KO neurons (Kneussel 
et al. 1999). Importantly, gephyrin is required for synaptic clustering of some, but not all subtypes 
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of GABA receptors (Kneussel, Brandstatter, et al. 2001), pointing out to existence of additional 
factors that modulate the receptor content of the synapse. 
 
S-SCAM is an additional scaffold protein that, unlike gephyrin, is expressed both at excitatory and 
inhibitory synapses. At inhibitory synapses, it binds several proteins including core inhibitory 
synaptic protein Neuroligin 2 (see below) and notably, an adhesive dystrophin glycoprotein 
complex that was proposed to mediate multiple synaptic functions such as transsynaptic signal 
transduction, cytoskeleton rearrangement and focal adhesion (Lévi et al. 2002). S-SCAM therefore 
may expose the core components of inhibitory synapse to modulation by extrasynaptic signals, 
adding another level of complexity to functional regulation of inhibitory synapses. 
 
1.4.3 Cell Adhesion Proteins of Inhibitory Synapses 
 
Postsynaptic targeting of GABA receptors to precisely oppose presynaptic vesicle release sites is 
essential for neural signalling and requires coordinated organization of pre- and postsynaptic 
compartments during synaptic maturation. Cell adhesion proteins such as the presynaptic 
Neurexins and the postsynaptic Neuroligins (Nlgns) stabilize the synapse following synaptic 
assembly. During early stages of synaptic maturation, Neurexins and Nlgns interact 
transsynaptically to drive clustering of core components of pre and postsynaptic sites, respectively 
(Craig & Kang 2007; Krueger et al. 2012). Specifically, establishment of initial synaptic contact 
triggers postsynaptic clustering of Nlgns, which in turn recruits scaffold proteins and receptors to 
the postsynaptic sites. Simultaneously, clustering of Neurexins is important for organizing the 
presynaptic vesicle release machinery (Dean et al.; 2003; Graf et al. 2004; Dean & Dresbach 2006). 
Nlgn- Neurexin interactions are therefore crucial for equipping the nascent synapse with core 
proteins that mediate synaptic signalling. 
 
Following synaptic specialization, Nlgns and Neurexins stay attached to each other and physically 
reinforce the synaptic contact as long as the synapse is active (Chubykin et al. 2005). Apart from 
synaptic stabilization, Nlgns stabilize the postsynaptic density by binding scaffold proteins and 
receptors at the post synaptic sites (Krueger et al. 2012). Additionally, intracellular Nlgn  
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Figure 1.4| Synaptic interactions of Nlgn2 at inhibitory synapses. Adapted from Krueger et al. 2012. 
 
 
interactions likely promote the clustering of receptors in an activity dependent manner, thus 
plastically enhancing the synaptic function in highly active networks (Hu et al. 2015).While the 
precise molecular mechanisms of their function are unknown, it is evident that Nlgns are essential 
for structural and functional aspects of the synapse.  
 
The Nlgn family is encoded by five genes in humans NLGN1, NLGN2, NLGN3 
NLGN4 and NLGN4Y, with NLGN4Y being absent from rodents (Ichtchenko et al. 1996). Nlgn1 
and Nlgn2 act exclusively at excitatory and inhibitory synapses, respectively, while Nlgn3 is 
localized to both types and Nlgn4 is localized to inhibitory glycinergic synapses in retina and brain 
stem, and hippocampus (Varoqueaux et al. 2006; Budreck & Scheiffele 2007; Hoon et al. 2011; 
Hammer et al. 2015). This differential expression allows each Nlgn to specify the functional 
properties of distinct types of synapses, such that Nlgn1 regulates the maturation and function of 
excitatory synapses and Nlgn2 of inhibitory synapses.  
 
1.5 Nlgn2 is An Inhibitory Synaptic Organizer 
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Figure 1.5| Nlgn2- Gephyrin- GABAA receptor complex.  
Nlgn2 tethers gephyrin to post synaptic membrane and together Nlgn2 and gephyrin recruit GABA 
receptors to the inhibitory synapses. CB- collybistin. Adapted from Poulopoulos et al. 2009. 
 
 
Nlgn2 is the first known adhesion protein constitutively present at inhibitory postsynaptic sites, 
where it assembles the synaptic components during synaptic maturation and maintains synaptic 
function of mature synapses via its multiple intracellular and extracellular interactions 
(Varoqueaux et al. 2006; Poulopoulos et al. 2009). Nlgn2 structurally and functionally couples pre 
and postsynaptic sites via interaction with Neurexin and mediates inhibitory specification and 
function via interactions with scaffold proteins and GABAA receptors (Poulopoulos et al. 2009; 
Nguyen et al. 2016, Figure 1.4).  
 
The most well-characterized postsynaptic function of Nlgn2 is activation of the gephyrin- 
collybistin complex. Nlgn2 binds gephyrin through a fifteen amino acid stretch at its cytoplasmic 
tail and simultaneously activates collybistin, which in turn targets gephyrin to the synaptic 
membrane (see above) (Poulopoulos et al. 2009, Figure 1.5).  The amount of Nlgn2- gephyrin 
complexes at postsynaptic sites determines the amount of functional GABAA receptors and the 
amplitudes of post synaptic inhibitory currents (Poulopoulos et al. 2009; Antonelli et al. 2014), 
demonstrating the central role of Nlgn2 in assembly of the post synaptic machinery.  
 
Nlgn2 may influence GABAergic transmission by directly binding to specific subunits of GABA 
receptors and inducing their clustering independently of gephyrin (Dong et al. 2007). Supporting 
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this notion, Nlgn2 was shown to promote the incorporation of GABAr1 subunit into functional 
GABA receptors,  leading to alteration in kinetics of inhibitory currents (Fu & Vicini 2009). These 
findings suggest that Nlgn2 shapes inhibitory synaptic function not only by determining the 
number of GABA receptors, but also by specifying their functional properties.  
 
In addition to interaction with gephyrin- collybistin complex and GABA receptors, Nlgn2 binds 
to  -dystroglycan, an S-SCAM and actin binding protein (Sumita et al. 2007; Woo et al. 2013). 
While the functional importance of these interactions was not experimentally addressed so far, it 
was proposed that S-SCAM may stabilize the synaptic localization of Nlgn2 and may mediate a 
cross talk between Nlgn2 and extrasynaptic proteins (Fritschy et al. 2012; Woo et al. 2013). In 
summary, the wealth of synaptic interactions enables Nlgn2 to organize and regulate inhibitory 
synaptic transmission throughout all stages of life of the synapse. 
 
1.6 Nlgn2 Function in the Brain 
 
Studies in vivo indicate that Nlgn2 stabilizes the synaptic structure once the initial synaptic contact 
is formed, hence determining the number of functional inhibitory synapses in each neuron 
(Chubykin et al. 2007; Jedlicka et al. 2011).  Consequently, Nlgn2 maintains synaptic transmission 
at the inhibitory synapses in cortex, hippocampus, midbrain, cerebellum and retina (summarized 
at table 1.2; Gibson et al. 2009; Poulopoulos et al. 2009; Hoon et al. 2009; Jedlicka et al. 2011; 
Zhang et al. 2015). All of these studies found that Nlgn2 is not involved in any aspect of maturation 
and function of excitatory synapses, validating the role of Nlgn2 as organizer of exclusively 
inhibitory synaptic function. 
 
Does Nlgn2 acts at all inhibitory synapses in the brain? The answer, based on cell region- specific 
quantification of GABA receptors, analysis of kinetics of inhibitory currents and modelling of 
inhibitory transmission in Nlgn2 KOs, appears to be negative. According to these studies, Nlgn2 
regulates the function of specifically perisomatic inhibitory synapses (Poulopoulos et al. 2009; 
Jedlicka et al. 2011), which points to either a cell region- specific function and/or, as most of 
perisomatic synapses in cortical structures are formed by Parvalbumin positive neurons, a cell 
type- specific function. Consistent with both notions, Nlgn2 does not regulate the function of 
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inhibitory terminals formed by Somatostatin positive neurons, which mainly contact dendrites 
(Gibson et al. 2009). Therefore, Nlgn2 regulates the function of subpopulation of inhibitory 
synapses.  
 
The functional specificity of Nlgn2 cannot be explained by its differential expression at cellular 
compartments, as Nlgn2 is expressed in the majority of inhibitory synapses, including dendritic 
synapses (Varoqueaux et al. 2004). Therefore, there must be synaptic factors that limit the function 
of Nlgn2 to specific subpopulation of synapses. Given that Nlgn2 regulates differential aspects of 
inhibitory transmission in distinct brain regions (Table 1.2), these factors must fine- tune Nlgn2 
function in brain region- specific manner.  
 
Table 1.2| Summary of electrophysiological characterization of Nlgn2 KO. 
 
mIPSC sIPSC eIPSC 
Brain region Frequency Amplitude Frequency Amplitude Amplitude 
      
Cerebellum 
(Purkinje 
cells)*1 
~ 70% decrease ↔ 
  
~ 50% 
decrease 
Medulla2 ~ 70% decrease ~ 25% decrease ~ 70% decrease ~ 50% decrease 
~ 50% 
decrease 
Hippocampus 
(CA1)2 
~ 50% decrease ↔ ~ 50% decrease ↔  
Hippocampus 
(dentate 
gyrus)3  
↔ ~ 25% decrease 
  
 
Somatosensory 
cortex4 
↔ ~ 25% decrease 
    
~ 50% 
decrease 
 
* Conditional KO restricted to cerebellum. 
sIPSC- spontaneous inhibitory postsynaptic currents, eIPSC- evoked inhibitory postsynaptic currents. 
1. Zhang et al. 2015   2. Poulopoulos et al. 2009   3. Jedlicka et al. 2011   4. Gibson et al.2009 
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To summarize, Nlgn2 critically functions to maintain inhibitory synaptic transmission at 
perisomatic synapses. The precise role of Nlgn2 in individual aspects of neural transmission (e.g 
vesicle release, number of active synapses, composition of receptors), as well as mechanisms that 
define synapse- specific Nlgn2 function, are currently unknown. 
 
1.7 Nlgn2 Mutations in Neuropsychiatric Diseases 
 
The prominent role of Nlgn2 in organizing the inhibitory synapse positions Nlgn2 as a potential 
contributor to cognitive diseases associated with altered synaptic function, such as autism spectrum 
disorder (ASD) and schizophrenia (Thomas C. Südhof 2008; Harrison & Weinberger 2005; 
Rubenstein & Merzenich 2003). Supporting the involvement of Nlgns in neuropathophysiological 
conditions, multiple mutations in Nlgn3 and Nlgn4 were identified in patients with ASD (Zoghbi 
& Bear 2012). Moreover, six missense mutations in Nlgn2 were identified in a cohort of patients 
with schizophrenia, including a loss-of-function mutation that decreased GABAergic synaptic 
function (Sun et al. 2011).  Additionally, one study found a duplication in gene region that includes 
Nlgn2 gene in patient with mental retardation (Belligni et al. 2012), although the contribution of 
other genes from the duplicated region to the phenotype was not ruled out.  
 
Recently, a de-novo heterozygous nonsense mutation in Nlgn2 was reported in a patient with 
severe anxiety, obsessive- compulsive behaviors, autism, short attention span and global 
developmental delays (Parente et al 2016). No other clinically- relevant mutations were present in 
this patient, suggesting that the phenotype was caused by the Nlgn2 mutation. Anxiety and 
schizophrenia are co- morbid conditions (Braga et al. 2013), and pathophysiology of both is 
strongly linked to deficits in inhibitory transmission (Rubenstein & Merzenich 2003; Lewis et al. 
2005), which may explain how Nlgn2 mutations contribute to two distinct neuropsychiatric 
conditions. However, the exact neural substrate affected by mutations of Nlgn2 in vivo is not fully 
described. 
 
1.8 Nlgn2 in Maintenance of Excitation/Inhibition Ratio in Vivo 
 
Given that Nlgn2 specifically regulates inhibitory transmission, it was proposed that Nlgn2 
mutations may lead to pathophysiological conditions by altering the ratio of excitation to inhibition 
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in brain regions implicated in autism and schizophrenia, such as prefrontal cortex and 
hippocampus (Amaral et al. 2008; Harrison & Weinberger 2005). This hypothesis was tested in 
several studies that manipulated Nlgn2 levels or disrupted its function in vivo. Overexpression of 
Nlgn2 increased synaptic inhibitory transmission in prefrontal cortex and led to deficits in social 
interactions. Additionally, enhancement of Nlgn2 expression and pharmacological dissociation of 
Nlgn2 from Neurexin1 in hippocampus of adult mice decreased and increased social aggression, 
respectively, as well as increased anxiety (Hines et al. 2008; Kohl et al. 2013; van der Kooij et al. 
2014). Finally, conditional deletion of Nlgn2 in medial prefrontal cortex of adult mice increased 
the excitation/inhibition ratio of pyramidal neurons, which was accompanied by decreased anxiety 
and fear conditioning deficits, but not by prominent social behavioral deficits (Liang et al. 2015). 
Interestingly, pharmacological disruption of Nlgn2 extracellular function in prelimbic cortex, one 
of the regions of medial prefrontal cortex, enhanced certain aspects of fear- related learning (Ye et 
al. 2016). These studies show that Nlgn2 continuously maintains inhibitory transmission at mature 
synapses and that Nlgn2 is critically involved in regulation of clinically- relevant phenotypes, and 
thus may be a novel pharmaceutical target. However, a variety of phenotypes reported in these 
studies strongly suggest that Nlgn2 function in vivo is highly dependent on a brain region, limiting 
the applicability of region-specific conditional KO to human patients with global Nlgn mutations. 
 
1.9 Behavioral Characterization of Nlgn2 KO 
 
In light of attention that loss-of-function mutations in Nlgn2 received due to their link to ASD, it 
is surprising that only two studies so far aimed to understand the contribution of constitutive Nlgn2 
KO to autism-related phenotypes. These studies reported that social interactions, measured as 
mouse interaction with mouse vs object and novel mouse vs familiar mouse, are not reduced in 
Nlgn2 KO, demonstrating that Nlgn2 is not involved in regulation of one of the core symptoms of 
ASD (Wöhr et al. 2014; Blundell et al. 2009). One study found a prominent reduction in locomotor 
activity in Nlgn2 KO (Wöhr et al. 2014), which was detected while mice explored a novel 
environment, and hence may be a product of novelty- induced freezing rather than locomotor 
impairment. The results of all the behavioral tests performed on Nlgn2 KO are summarized in 
table 1.3. 
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Table 1.3| Summary of behavioral deficits in Nlgn2 in comparison to WTs. 
 
* Blundell et al. reported that locomotor activity is not altered in Nlgn2 KOs. 
1. Blundell et al. 2009   2. Wöhr et al. 2014 
   
As loss-of-function mutation of Nlgn2 was recently identified in a patient with severe anxiety 
(Parente et al. 2016), it is particularly important that a prominent anxiety related phenotype was 
reported in Nlgn2 KO mice (Blundell et al. 2009).  This indicates that Nlgn2 must play a central 
role in the neural circuitry underlying anxiety behaviors, but to date, virtually nothing is known 
about the function of Nlgn2 in these circuits. 
 
1.10 IgSF9b- a Novel Synaptic Partner of Nlgn2 
 
The known synaptic partners of Nlgn2 including Neurexins, gephyrin, collybistin and GABAA 
receptors majorly contribute to maintenance of inhibitory synaptic transmission, highlighting the 
central role of Nlgn2 at the inhibitory synapse. Recently, the adhesion protein IgSF9b was shown 
to interact with Nlgn2 through common binding to scaffold protein S-SCAM (Figure 1.6) and to 
regulate the number of inhibitory contacts onto inhibitory interneurons (Woo et al. 2013). These 
features indicate that IgSF9b may be a novel inhibitory synaptic regulator that modulates the 
function of Nlgn2. 
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2
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motor 
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1,2
Social 
behavior
2
OFT
1
LD
1,2
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2
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↔
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light zone 
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IgSF9b belongs to a superfamily of IG adhesion proteins reported to regulate dendritic arborisation 
and synaptic maturation (Shi et al. 2004). IgSF9b is a transmembrane protein that contains five Ig 
domains, two fibronectin domains, one transmembrane domain and a C-terminal with PDZ binding 
motive. IgSF9b was recently identified as a novel inhibitory synaptic adhesion protein that is 
selectively present at inhibitory synapses. While precise role of IgSF9b in inhibitory circuits was 
not studied in vivo, post synaptic knockdown of IgSF9b in hippocampal cell cultures reduced the 
number of inhibitory synapses and decreased the frequency of mIPSCs, indicating that IgSF9b 
may regulate inhibitory synaptic development and/or maturation. Although the subcellular 
expression pattern and the function of IgSF9b closely resemble those of Nlgn2, there are three 
important distinctions.  First, IgSF9b can mediate homophilic adhesion, indicating that IgSF9b 
function may not be limited to post synaptic sites. Second, IgSF9b is expressed at the periphery, 
and not at the core, of inhibitory synapses. Finally, IgSF9b predominantly regulates inhibitory 
transmission of synapses formed onto inhibitory neurons (Woo et al. 2013). Taken together, this 
suggests that IgSF9b and Nlgn2 may regulate inhibitory function by distinct mechanisms. 
Considering that both IgSF9b and Nlgn2 interact with S-SCAM, IgSF9b may modulate the 
synaptic function of Nlgn2 in specific populations of inhibitory synapses. 
 
IgSF9b was linked to major depressive disorder, but its physiological function in vivo was not 
studied (Shyn et al. 2011). As major depressive disorder shows high co-morbidity with anxiety 
(Kendler et al. 1992), and in light of possible interaction of IgSF9b with anxiety- related Nlgn2, 
investigating the interaction of both IgSF9b and Nlgn2 in regulation of inhibitory transmission in 
anxiety processing circuit may lead to important insights into molecular mechanisms of anxiety. 
Figure 1.6| Interaction of IgSF9b and Nlgn2 at the post synaptic membrane. Adapted from Woo et al. 
2013. 
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1.11 Aim of the Project 
 
This project aims to characterize the molecular mechanisms underlying anxiety- related 
disorders by investigating the function of two synaptic adhesion proteins, Nlgn2 and IgSF9b, in 
the anxiety processing circuit. Specifically, I address two questions: 
 
1. What is the circuit, cellular and synaptic mechanism underlying anxiety- like phenotype of 
Nlgn2 KO mice? 
 
2. Does IgSF9b deletion modulate the anxiety- like phenotype of Nlgn2 KO mice and if yes, what 
is the circuit, cellular or synaptic mechanism underlying this modulation? 
 
To address these questions, I use a top-bottom approach (Figure 1.7) first identifying the brain 
regions, then identifying the type of neurons (excitatory vs inhibitory) and finally the synaptic 
proteins which function is altered in Nlgn2 KO and/or IgSF9b KO mice. My work describes, for 
the first time, the function of synaptic adhesion proteins in the inhibitory circuitry of amygdala 
and their profound impact on anxiety- related processing in vivo and anxiety- related behavior. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7| Framework for studying the role of Nlgn2 and IgSF9b in anxiety- related brain regions.
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2. MATERIALS AND METHODS 
 
2.1 Experimental Animals 
 
Nlgn2 KO mice (14) were generated in our laboratory on an 129/Sv background and were 
backcrossed onto a C57BL/6J background for at least six generations. Male wildtype (WT), 
heterozygous (Het) and homozygous (KO) littermates were obtained from Nlgn2 heterozygous 
breeding pairs. IgSF9b KO mice were obtained from Lexicon Pharmaceuticals (The Woodlands, 
TX, U.S.A.; Omnibank clone 281214, generated through insertion of the Omnibank gene trap 
vector 48 into the IgSF9b gene in Sv129 ES cells) and were backcrossed onto a C57BL/6J 
background for at least six generations. Nlgn2 KO mice and IgSF9b KO mice were crossed to 
generate Nlgn2 het x IgSF9b het breeding pairs, from which four experimental genotypes were 
obtained as littermates, i.e. WT, Nlgn2 KO, IgSF9b KO and double KO mice. For in vitro 
electrophysiology experiments, these mice were additionally crossed with mice expressing a 
Venus transgene under the control of the VGAT promoter to label inhibitory interneurons (Wang 
et al. 2009, Neuroscience 164:1031-1043). All mice were 2-3 months old at the beginning of the 
experiment. Animals were maintained on a 12 hour light/dark cycle, with food and water ad 
libitum. All experiments were performed during the light cycle (with the exception of home cage 
activity monitoring of Nlgn2 KO mice as described below). The experimenter was blind to 
genotype during all stages of data acquisition and analysis. All procedures were carried out in 
agreement with the guidelines for the welfare of experimental animals issued by the Federal 
Government of Germany and the Max Planck Society. 
 
2.2 Behavioral Characterization 
 
Assessment of anxiety. To assess anxiety levels, cohorts of Nlgn2 KO, Nlgn2 Het and WT mice 
were subjected to the following three anxiety tests on consecutive days: Elevated plus maze (EPM), 
open field test (OFT) and light/dark test (LDT). These tests are well- validated anxiety assays 
(Carola et al. 2002) and measure the extent of avoidance of naturally aversive environments: the 
open arms of elevated plus maze (EPM), the center of the open field chamber (OFT) and the 
brightly lit areas (LDT). The following parameters were assessed: EPM, total distance travelled in 
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the open and closed arms, distance travelled in the open arms, number of entries to the open arms, 
time spent in the open arms; OFT, total distance travelled in the OF chamber, distance travelled in 
the center zone, distance travelled in the periphery zone, number of entries to the center zone, time 
spent in the center zone; LD, distance  travelled in the light zone, number of entries to the light 
zone, time spent in the light zone. 
 
To assess anxiety levels in Nlgn2 KO, IgSF9b KO, double KO and WT mice, exclusively OFT 
was used. Each group of four male or female mice including one mouse of each genotype was 
tested on a separate day. The following parameters were assessed: total distance travelled in the 
OF chamber, distance travelled in the center zone, distance travelled in the periphery zone, number 
of entries to the center zone, time spent in the center zone, distance travelled in the intermediate 
zone, number of entries to the intermediate zone, time spent in the intermediate zone.  
 
Detailed parameters for each test are listed in Table 2.1. Performance was recorded using an 
overhead camera system and scored automatically using the Viewer software (Biobserve, 
Germany).   
 
Table 2.1| Parameters for anxiety measurements 
 
Test Dimensions of chamber Light 
intensity 
Placement of 
mouse 
Duration of 
assessment 
     
     
Elevated 
plus maze 
Two open arms 28 x 5 cm 
Two closed arms 28 x 5 cm (walls 15 cm) 
Center zone 5 x 5 cm 
90 lux Closed arm 5 min 
     
Open field 
test 
Arena 50 x 50 cm (walls 50 cm high) 
Center zone 25 x 25 cm 
Intermediate zone surrounding the center 
zone 6.25 cm at each direction 
20 lux Corner of 
periphery 
10 min 
     
     
Light/dark 
test 
Open (light) compartment 25 x 25 cm 
Closed (dark) compartment 25 x 25 cm 
140 lux Closed 
compartment 
5 min 
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Assessment of home cage activity. Recording of home cage activity was performed using the 
LABORAS system and software (Metris, Netherlands). The following aspects of activity were 
recorded: total distance travelled and duration of locomotion, immobility, climbing, grooming and 
circling. A detailed description of the assessment of home cage activity can be found in table 2.2. 
 
Table 2.2| Measurement of home cage activity 
 
Day  Description  Duration  
   
1,2  Habituation to the room and to the cage,  
in individual cages (20 x 25 cm) 
17:00 - 09:00,  
dark cycle: 19:00 - 07:00 h 
  
3 Transfer of the cages onto vibration sensitive platforms and 
recording of activity with LABORAS (Metris, Hoofddorp, The 
Netherlands) 
 
Assessment of freezing in a novel environment. Mice were placed inside a fear conditioning 
chamber (25 x 30 cm, Med Associates) with a camera fixed on one of the internal walls. Freezing 
behavior was recorded for a period of 2 minutes and scored automatically using the Video Freeze 
software (Med Associates) with the motion detection threshold set to 60.  
 
2.3 In vitro Electrophysiology 
 
Preparation of slices. Adult (8-12 weeks) mice were anesthetized with Avertin and perfused 
transcardially for 90 seconds with ice-cold sucrose solution, as described for the preparation of 
amygdala slices taken from adult animals (Adhikari et al. 2015). The brains were rapidly dissected 
and placed in the same sucrose solution, the brainstem dissected and the brains mounted on holder 
and transferred to vibrotome chamber filled with sucrose solution. After slicing, 300 m coronal 
sections containing basal and central amygdala were transferred to a holding chamber filled with 
artificial cerebrospinal fluid (aCSF) equilibrated with 95% O2/5% CO2.  Slices were allowed to 
recover for 20 minutes at 33 Cº and then maintained at the room temperature.  
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Patch clamp recording.  Whole-cell patch clamp recordings were obtained at room temperature 
(22 Cº) with EPC10 amplifier. Slices were kept in a recording chamber and perfused with aCSF at 
the rate of 1-2 ml/min. Neurons were visually identified with infrared video microscopy using an 
upright microscope equipped with a 60X objective.  Patch electrodes (resistance then filled with 
internal solution was 3–5 MΩ) were pulled from borosilicate glass tubes. For voltage clamp 
experiments to record miniature inhibitory post-synaptic currents (mIPSCs), patch electrodes were 
filled with Cs- based internal solution. To exclude glutamatergic inputs, NBQX (6-cyano-7-
nitroquinoxaline-2,3-dione, 2 μM: AMPA receptor antagonist) and A - CPP ((RS)-3-(2-
Carboxypiperazin-4-yl)-propyl-1-phosphonic acid, 2 μM: NMDA receptor antagonist) were added 
to the aCSF. To exclude action potential dependent IPSCs, tetrodotoxin (TTX, 1 µM) was added 
to the ACSF. Whole cell patch-clamp recordings were included in analysis if initial access 
resistance was below 13 MΩ and did not change for more than 20 percent; and the leak current 
was below 200 pA during the recording.  Data were acquired with Patchmaster software, filtered 
at 2 kHz and digitised at 20 kHz. Data was analysed in Igor Pro, using costume made algorithms 
of template matching to detect mini currents (Taschenberger et al. 2005). 
 
2.4 In vivo Electrophysiology 
 
Surgery Male mice were single housed for 7 days before the recording, and provided with food 
and water ad libitum. Experiments were performed during the light cycle. Mice were anesthetized 
with avertin (loading dose 2 mL/100 g, maintenance doze 0.2 mL/100 g intraperitoneal). 
Anesthetized mice were placed in a stereotaxic frame and their body temperature was monitored 
by a rectal probe and maintained at 36 °C. An incision in the midline of the scalp was made to 
expose the skull. Bregma and lambda were aligned to a plane level ± 50 μm. Multi-wire electrode 
array was unilaterally implanted targeting the left central medial nucleus (0.9 mm posterior, 2.3 
mm lateral and 5.04 mm ventral to the bregma). 
 
The electrodes consisted of 2 bundles (spaced 750-950 µm) of 8 individual insulated tungsten 
wires (13 µm inner diameter, impedance 60-100 kΩ) inserted into a polymide tube (127 µm inner 
diameter) and attached to an 18-pin connector. A reference screw was implanted above the 
cerebellum. The implant was secured with two screws implanted in the skull at ~300 µm lateral 
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and anterior to the electrode and bonded with dental cement. Immediately after the surgery, mice 
received subcutaneously analgesic (Carprofen 5mg/kg) and antibiotic (Baytril 5mg/kg). 24 hours 
after the surgery, mice received Caprofen (5mg/kg) subcutaneously and Baytril in the drinking 
water (0.2 mg/ml). Mice were sacrificed following the open field recording for histological 
verification of the recording site. 
 
Data acquisition. The experimental design is summarized at figure 2.1.  Electrophysiological 
signal was amplified and sent to acquisition board. The raw signal was acquired at 32 kHz 
sampling rate, bandpass filtered (0.1-9000 Hz) and stored for offline analysis. During the 
experiment, simultaneous electrophysiological and video recordings were made by Cheetah Data 
Acquisition System (Figure 2.2). 
 
 
Figure 2.1| Stages of in vivo electrophysiology experiment.  
 
Data analysis Local field potentials were analyzed in custom-written MATLAB scripts. The 
signal was filtered between 0.7 and 400 Hz using a zero-phase distortion FIR filter and down 
sampled to 1 kHz. For the power and coherence analysis we used the multitaper method (Chronux 
Package) (Mitra & Bokil 2007), using 5 tapers (discrete prolate spheroidal sequences) with a time 
bandwidth product of 3, and 0.1 seconds overlap.  
 
For each mouse, we extracted the time periods and the trajectory of the movement in the periphery 
and center using a modified version of the autotyping toolbox (Patel et al. 2014). For the power 
correlations as a function of time spent in the center, first we summed the power  
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Figure 2.2| In vivo recording of CeM activity. Mouse in the open field during recording session (left) and 
an example of power spectrum of local field potential obtained during the exploration of the open field 
(right).    
 
across the gamma frequency band (70-120 Hz), and then we averaged the summed values across 
all the time points spent either in the center or periphery. Using this average power values 
obtained from the periphery and the center we computed the ratio (center/periphery) for each 
mouse and calculated the linear correlation coefficient (fit function, MATLAB) including mice 
from all genotypes.  
 
To evaluate power changes during transition periods from periphery to the center, we extracted all 
the trials at which the mouse shuttled from the periphery to the center and back to periphery during 
≤ 10 seconds.  Extracted trials were aligned so the time points at which mice were at the minimum 
distance from the center at each trial overlapped. The power values at each time point were z-score 
transformed to a baseline defined as the initial 3 seconds of each trial as follows: 
𝑧𝑠𝑐𝑜𝑟𝑒(𝑡) =
𝑃(𝑡) − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
𝑠𝑡𝑑(𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒)
 
 
Where 𝑧𝑠𝑐𝑜𝑟𝑒(𝑡) is the z-score at each time point 𝑡, 𝑃 is the power value of a given frequency, 
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 is the average power of the baseline and 𝑠𝑡𝑑(𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒) is the standard deviation of the 
baseline period. For the analysis of power change of the gamma band during transition periods, 
we average the z-scored values across the gamma range (70-120 Hz) at each time point.  
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2.5 Immunohistochemistry Procedures 
 
Paraformaldehyde perfusion fixation. Animals were anesthetized with Avertin (500 ul/25 gram) 
and perfused transcardially with 0.9% sodium chloride at pH 7.4 for 1 minute, followed by 
perfusion with 4% paraformaldehyde diluted in 0.1 M phosphate buffer (PB) for 8 minutes. The 
brains were dissected and post- fixed overnight at 4°C in 4% paraformaldehyde diluted in 0.1M 
PB. On the following day, the brains were transferred to 30% sucrose solution in 0.1M PB and 
kept for 1-2 days at 4°C prior the slicing. The brains were sliced in cryostat at temperature of -18 
Cº. Free floating coronal slices were collected in PBS. The slices were washed in phosphate buffer 
saline (PBS), blocked for one hour, incubated with primary and secondary antibodies (Table 2.7), 
mounted on glass slides using Aqua-Poly/Mount, dried overnight at 4 Cº and covered with glass 
coverslips. Sections were washed with PBS after each incubation. Blocking and staining conditions 
are specified in the table 2.3. 
 
Methanol fixation of fresh frozen brains. Animals were decapitated and the brains were 
dissected and rapidly frozen in an isopentane bath at -38°C. The brains were sliced in cryostat at 
temperature of -18 Cº. Coronal sections of amygdala were mounted on glass slides inside the 
cryostat and dried for 40 minutes at room temperature. Sections were then fixed in methanol at -
20°C for 5 minutes, blocked for 1 hour, washed with PBS and incubated with primary and 
secondary antibodies (Table 2.7), dried overnight at 4 Cº and covered with glass coverslips. 
Blocking and staining conditions are specified in the table 2.3. 
 
2.6 cFOS Assay 
 
Measuring the expression of neuronal activity marker cFOS (Sagar et al. 1988) was used to assess 
the neuronal activity of brain regions involved in anxiety- related processing, including amygdala 
nuclei and prefrontal cortex (summarized at table 2.4).  
 
To induce cFOS activation across components of anxiety- processing circuitry, mice were taken 
from their home cages and exposed to novel environment (open field chamber) for 10 minutes. 
After the exposure to the open field, mice were returned to their home cages and kept there for 90 
minutes to allow for expression of cFOS. After 90 minutes in the home cages, mice were sacrificed 
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and perfused with 4% PFA as described above. Brains were dissected and processed as described 
above for paraformaldehyde perfusion- fixed slices. The stages of cFOS activation assay are 
summarized at figure 2.3. Blocking and staining conditions for cFOS labelling are specified in the 
table 2.3. 
 
 
 
Figure 2.3| Stages of cFOS  assay.  
 
Table 2.3| Immunolabeling conditions. 
 
 
 
Experiment overview 
Fixation 
Method 
Slicing Blocking solution 
 
- Co-labeling cFos and 
Somatostatin 
 
Perfusion with 
4% paraform-
aldehyde 
 
Free floating 
coronal 
sections, 
40 µm 
 
10% donkey serum and 
0.3% Triton in PBS 
-Co-labeling cFos and 
Parvalbumin/CAMKII 
 
-Co-labeling VIAAT and Vglut2 
 
-Labeling VGAT, cFos or GFP 
3% BSA, 10 % goat 
serum and 0.3% Triton 
in PBS 
 
 
-Labeling Gephyrin, PSD-95, S-
SCAM, GABAAα1, GABAAγ2, 
GABAAα2, Nlgn2 or IgSF9b 
 
-Co-labeling Nlgn2 with 
Gephyrin/PSD-95 
 
-Co-labeling IgSF9b with Nlgn2/ 
Gephyrin/ VGAT/ Vglut 2/ 
Ankyrin G/PSD-95 
 
 
Methanol 
fixation of fresh- 
frozen brains 
 
 
Coronal 
sections, 
20 µm, 
mounted on 
slides before 
blocking 
 
 
3% BSA,10 % goat 
serum and 0.3% Triton 
in PBS 
Habituation to testing room
3-4 hr
Open field test
10 min
Home cage
90 min
Perfusion
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Table 2.4| Brain regions assesed in cFOS activation assay 
 
 
2.7 Image Acquisition and Data Analysis   
 
General comments. Images were acquired using a confocal laser scanning microscope (Leica 
SP2). For each WT-KO pair, sections were anatomically matched and the settings for laser power, 
gain and offset were kept constant during imaging.  Detailed description of acquisition parameters 
and analysis methods appears in table 2.5. 
 
Imaging of synaptic markers. Images of synaptic markers (gephyrin, PSD- 95, Nlgn2 and 
VIAAT) were obtained using a 63x oil immersion objective. The number and size of particles, as 
well as mean fluorescence intensity, were quantified in the area surrounding the cell body, and the 
number of particles per area was divided by the length of the perimeter to obtain the final result, 
as demonstrated in figure 2.4. Colocalization of synaptic markers was analyzed using Imaris 
software using coloc function.  
 
Brain region Subregions Coordinates from bregma 
 
Medial prefrontal cortex 
 
Infralimbic cortex 
 
 
2.8 mm - 1.94 mm 
Prelimbic cortex 
 
Amygdala 
 
 
Basal amygdala, anterior 
 
-0.94 mm - -1.28 mm 
 
Basal amygdala, posterior 
 
-1.28 mm - -1.77 mm 
 
Central lateral amygdala 
 
-0.94 mm - -1.64 mm 
 
Central medial amygdala 
 
-0.94 mm - -1.64 mm 
 
Lateral amygdala 
 
-1.28 mm - -1.77 mm 
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Figure 2.4| Stages in quantification of synaptic markers.  
A. Photomicrograph of an optical section with delineated perimeter of the cell body. 
B-C.   Quantification of synaptic puncta in ImageJ- thresholding (B), applying segmentation algorithm to 
separate puncta (C) and applying “analyze particles” to outline and count the puncta (D). 
 
Imaging of cFos, cellular markers and retrobeads. Images of cFos, cellular markers and 
retrobeads (see next section) were obtained using a 40x oil immersion objective as described in 
table 2.6. cFos images were thresholded manually in ImageJ with same threshold value for WT 
and Nlgn2 KO in each pair. cFos images were tresholded in ImageJ (Figure 2.5), and single- and 
double-labeled cells were then quantified using Imaris (Bitplane, Zurich, Switzerland) as 
demonstrated at figure 2.6.  
 
 
 
Figure 2.5| Thresholding in ImageJ. Photomicrograph of cFOS expression before (A) and after (B) 
thresholding in ImageJ. 
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Figure 2.6| Colocalization of cFOS positive neurons with cellular markers in IMARIS.  
A. Thersholded cFOS photomicrograph (upper image) and cFOS positive cells detected in IMARIS (lower 
image, blue spots) 
B. CAMKII photomicrograph before (upper image) and after detection of CAMKII positive cells in 
IMARIS. “create surface” algorithm was used to mark the CAMKII positive cells (lower image, yellow 
spots). 
C. cFOS spots with CAMKII surfaces before application of “find spots close to surfaces” algorithm in 
IMARIS. 
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Table 2.5| Image acquisition and image analysis parameters 
Experiment  
Magnifi- 
cation 
Stack thickness, 
number of 
sections 
Total number 
of images/ 
stacks/animal  
Thresholding 
and analysis 
Nlgn2/gephyrin 
colocalization; 
Nlgn2/PSD-95 
colocalization 
 63x 
Digital 
zoom: 
8x 
N/A 3 images (1 
image /slice) 
Automatic threshold and degree of 
colocalization both assed with “coloc” 
tool in IMARIS (Bitplane, Zurich, 
Switzerland) 
Quantification  
of VIAAT and 
gephyrin-
positive puncta 
 63x 
Digital 
zoom: 
8x 
2 µm, 
2 sections 
18 stacks 
imaged from 
6 slices (3 
stacks/slice) 
Thresholded manually in ImageJ, 
quantification performed with “count 
particles” module in ImageJ 
Quantification 
of PV-positive 
puncta 
 40x 5 µm, 
2 sections 
10 stacks 
imaged from 
5 slices (2 
stacks/slice) 
Quantification with “create spots” tool 
in IMARIS (Bitplane, Zurich, 
Switzerland) 
Quantification 
of cFOS 
positive cells,  
baseline cFOS 
expression 
 40x 10 µm, 
4 sections 
5 stacks 
imaged from 
5 slices (1 
stack/slice) 
Manual threshold set as 3*background 
intensity and thresholded in ImageJ, 
quantification with “create spots” tool 
in IMARIS (Bitplane, Zurich, 
Switzerland) 
Quantification 
of cFOS 
positive cells in 
cortical regions 
 40x 10 µm, 
4 sections 
5 stacks 
imaged from  
5 slices (1 
stack/slice) 
Manual threshold set as 3*background 
intensity and thresholded in ImageJ, 
quantification with “create spots” tool  
in IMARIS (Bitplane, Zurich, 
Switzerland) 
Quantification 
of cFOS in 
basal amygdala 
 40x 5 µm, 
2 sections 
10 stacks 
imaged from  
5 slices (2 
stacks/slice) 
Manual threshold set as 3*background 
intensity and thresholded in ImageJ, 
quantification with “create spots” tool  
in IMARIS (Bitplane, Zurich, 
Switzerland) 
Quantification 
of PV and SOM 
positive cells 
 40x 5 µm, 
2 sections 
10 stacks 
imaged from   
5 slices (2 
stacks/slice) 
Application of “median filter” tool to 
the images, and quantification using 
“create spots” tool, both with IMARIS 
(Bitplane, Zurich, Switzerland) 
Quantification 
of CAMKII 
positive cells 
 40x 2 µm, 
2 sections 
16 stacks 
imaged from  
8 slices (2 
stacks/slice) 
Application of “median filter” tool to 
the images, and quantification using 
“create spots” tool, both with IMARIS 
(Bitplane, Zurich, Switzerland) 
Colocalization 
of cFOS and PV 
and SOM 
 Imaged and thresholded as described above for cFOS and each marker, colocalized 
using “colocalize spots” tool in IMARIS (Bitplane, Zurich, Switzerland) for PV and 
SOM colocalization and “find spots close to surface” for CAMKII and retro beads 
colocalization 
MATERIALS AND METHODS 
 
32 
 
2.8 Retrograde Labeling of BA Neurons That Project to CeM 
 
Surgical procedure. Mice received intraperitoneal injection of Caprofen (5mg/kg) to reduce post-
surgery pain 30 minutes prior to surgery.  Mice were anaesthetized with Avertin by intraperitoneal 
injection (500 ul Avertin/25g body weight) and placed in digital stereotaxic frame. To bilaterally 
label BA neurons projecting to the CeM, 50 nl of red retrobeads (excitation maximum at 530 nm 
and emission maximum at 590 nm) were injected into the CeM (0.70 mm posterior, ±2.35 mm 
medial and 5.08 mm ventral from bregma). A Hamilton syringe (1 ul) was used to manually deliver 
the retrobeads at the rate of 0.5 nL/s. After the injection was completed, the tip of the syringe was 
raised for 100 μm and left for 3 minutes to allow diffusion of the retrobeads at the injection site; 
and then slowly withdrawn at the rate of 1 mm/minute.  Following surgery, mice received 
Metamizol with drinking water (200 mg/kg/day, drinking rate estimated at 3 ml/day) for 3 days to 
reduce pain and risk of inflammation.  
 
Data acquisition and analysis. Mice were single housed for 7 days post-surgery to allow their 
full recovery and travelling of beads from the injection site up the axons of BA neurons to their 
somata. To induce anxiety associated activation of basal amygdala, mice were subjected to open 
field test with consecutive cFOS activation assay as described above. Only slices from brains in 
which injection sites did not exceed the borders of CeM (confirmed by visualizing the sites of 
injection on 5 subsequent coronal sections of amygdala spanning 400 µm of tissue, FigureX) were 
included in subsequent imaging and analysis. Data acquisition and quantification of cFOS positive 
cell bodies containing retrobeads was performed similarly to quantification of CAMKII - cFOS 
double labeled neurons as described above. 
 
Figure 2.7| Verification of retro beads injection site. Serial photomicrographs of amygdala slices with 
injection site in CeM (bright mark, right images) as compared to anatomical atlas (left image, adapted from 
Franklin and Paxinos, 2007). 
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2.9 Statistical Analysis 
 
All data were analyzed statistically using Prism (GraphPad Software, USA). Outliers, defined as 
two standard deviations from the mean, were removed prior to statistical analysis (maximum one 
outlier per group per experiment was detected). All the statistical tests conducted are summarized 
in table 2.6. 
 
Table 2.6| Statistical analysis 
 
 
 
Experiment Statistical test Post-hoc test 
   
Results- Part 1 
Behavioral characterization One-way ANOVA Tukey's test 
Quantification of cFOS and 
cellular markers 
 
Two- tailed paired Student's t-test 
Quantification of synaptic 
markers 
 
Two- tailed paired Student's t-test 
Patch clamp recording Two- tailed paired Student's t-test 
Results- Part 2 
Behavioral characterization Two- way ANOVA One- way ANOVA with Bonferroni's 
correction 
Quantification of cFOS and 
cellular markers 
Two-way ANOVA Two- tailed paired Student's t-test 
Quantification of synaptic 
markers 
Two-way ANOVA Two- tailed paired Student's t-test 
Patch clamp recording Two-way ANOVA Two- tailed paired Student's t-test 
 
Kolmogorov- Smirnov test 
Local field potentials 
recording in vivo 
Two-way repeated 
measures ANOVA 
Two- tailed paired Student's t-test 
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2.10 List of Antibodies 
 
Table 2.7| Primary and secondary antibodies. 
 
Antigen Primary antibody Secondary antibody 
 Species Dilution, 
duration of 
incubation 
 
Source Species Dilution, 
duration of 
incubation 
Source 
 
Ankyrin 
G      
 
Rabbit 
polyclonal 
 
1:1000, 
12 h 
 
Santa 
Cruz 
Biotech., 
Dallas, 
TX, USA 
 
Goat anti- 
rabbit 
A488 
 
1:600, 
2-h3 h 
 
Invitrogen 
Eugene, 
OR, USA 
CAMKII Mouse 
monoclonal
, clone 6G9 
 
1:2000, 
60 h 
Abcam 
Cambridg
e, MA, 
USA  
Goat anti-
mouse 
A555 
1:600, 
2-3 h 
Invitrogen 
Eugene, 
OR, USA 
cFOS Rabbit 
polyclonal, 
clone SC52 
1:2000, 
12 h 
Santa 
Cruz 
Biotech., 
Dallas, 
TX, USA 
Goat anti- 
rabbit 
A488 
1:600, 
 2-3 h 
Invitrogen 
Eugene, 
OR, USA 
*Donkey 
anti-rabbit 
A555 
1:600, 
2-3 h 
Mobitec, 
Goettingen 
Germany 
GABAAR 
α1 
Rabbit, 
polyclonal 
1:1000, 
12 h 
Synaptic 
Systems, 
Göttingen, 
Germany 
Goat anti- 
rabbit 
A488 
1:600, 
 2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
GABAAR 
α2 
Rabbit, 
polyclonal 
1:1000, 
12 h 
Synaptic 
Systems, 
Göttingen, 
Germany 
Goat anti- 
rabbit 
A488 
1:600, 
 2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
GABAAR 
γ2 
Guinea pig, 
polyclonal 
1:1000, 
12 h 
Fritschi 
lab 
Goat anti- 
guinea pig 
A555 
1:600, 
2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
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Gephyrin
1 
Mouse 
monoclonal 
clone 3B11 
1:1000, 
12 h 
Synaptic 
Systems, 
Göttingen, 
Germany 
Goat anti-
mouse 
A555 
 
1:600, 
2-3 h 
Invitrogen, 
Eugene, 
OR 
USA 
GFP Rabbit 
polyclonal 
 
1:500, 
12 h 
MBL, 
Nagoya, 
Japan  
Goat anti-
mouse 
A555 
1:600, 
2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
IgSF9b Rabbit 
polyclonal,  
clone  
1:1000, 
12h 
Sigma-
Aldrich, 
Munich, 
Germany 
Goat anti- 
rabbit 
A488 
1:600, 
2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
Nlgn2 Rabbit 
polyclonal 
 
1:500,  
12 h 
Brose lab Goat anti-
mouse 
A555 
1:600, 
2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
Parvalbu-
min 
Mouse 
monoclonal 
clone 
PV235 
 
1:4000, 
12 h 
SWANT, 
Bellinzon
a, 
Switzerlan
d 
Goat anti- 
mouse 
A555 
 
1:600, 
2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
PSD-95  Mouse 
monoclonal 
clone 
K28/43 
1:2000, 
12 h 
Neuromab
, 
UC Davis, 
CA, USA 
Goat anti- 
mouse 
A555 
 
1:600, 
2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
SOM Goat 
polyclonal, 
clone 
SC7819 
 
1:500, 
12 h 
Santa 
Cruz 
Biotech- 
nologies, 
Dallas, 
TX, USA 
Donkey 
anti-goat 
A488 
1:600, 
2-3 h 
 
Mobitec, 
Göttingen 
Germany 
S-SCAM Rabbit 
polyclonal 
 
1:1000, 
12 h 
Sigma-
Aldrich, 
Munich, 
Germany 
Goat anti-
rabbit 
A555 
1:600, 
2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
Vglut 2  Guinea pig, 
polyclonal 
1:1000, 
36 h  
Synaptic 
Systems, 
Göttingen, 
Germany 
Goat anti- 
guinea pig 
A555 
1:600, 
2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
                                                     
 Table 2.7 continued 
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VIAAT Rabbit 
Polyclonal, 
clone 
131003 
 
1:1000, 
36 h 
Synaptic 
Systems, 
Göttingen, 
Germany 
Goat anti- 
rabbit 
A488 
1:600, 
2-3 h 
Invitrogen, 
Eugene, 
OR, USA 
 
2.11 Solutions 
 
Immunohistochemistry 
 
Phosphate buffer saline (PBS) 
160g of NaCl, 4.0g KCl, 36.1g of Na2HPO4*2H2O, 4.8 KH2PO4 in DDW; total volume 2L; 
pH= 7.4. 
Phosphate buffer 0.2 M (PB) 
27.3g of Na2HPO4, 7.36g of NaH2PO4; total volume 1000 mL; pH=7.4. 
Sucrose solution 30% 
30g of sucrose in 0.1M PB; total volume 100 ml 
Paraformaldehyde solution 4% 
40g of paraformaldehyde in 0.1M PB; total volume 1L 
Normal saline solution 
9g of NaCl in DDW; total volume 1L 
Avertin 
4.5 mL normal saline,400 µl ethanol, 100 µl of avertin stock solution. 
Avertin stock solution  
5g 2,2,2- Tribromoethanol in 5 mL 2 methyl-2-butanol. 
 
In vitro electrophysiology 
 
10x ACSF stock solution  
72.47g of NaCl, 2.01g of KCl, 21.84g of NaHCO3, 1.725g of NaH2PO4 (1H2O) in DDW; total 
volume 1L 
Sucrose solution 
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6mM MgCl2, 0.1 mM CaCl2, 8.55g sucrose, 0.225g glucose, 0.284g of kynurenic acid in 
ACSF; total volume 500 mL 
Internal solution (patch pipette solution) 
110 mM CsCl, 30mM K-gluconate, 1.1mM EGTA, 10 mM HEPES, 0.1 mM CaCl2, 4 mM 
Mg-ATP, 0.3 mM Na-GTP and 4mM N-(2,6-Dimethylphenylcarbamoylmethyl) 
triethylammonium bromide (QX-314; Tocris-Cookson, Ellisville, MO); pH = 7.3 (adjusted 
with CsOH, 280 mOsm). 
External solution (Slice incubation solution) 
1.3 mM MgCl2, 2mM CaCl2, 2.51g glucose, 0.297g ascorbic acid in ACSF; total volume 750 
mL; osmolarity ≈ 320 mOsm. 
 
Stereotaxic surgery 
Sterile normal saline (0.9% NaCl in DDW).  
 
2.12 Materials 
 
Table 2.8| List of materials. 
 
Immunohistochemistry   Electrophysiology   Stereotaxic surgery 
  
Name Company Name Company Name Company 
2,2,2- Tribromoethanol  Alfa 
Aesar 
D-(+)- Glucose 
monohydrate 
Sigma- 
Aldrich 
Metamizol
e 
Ratiopharm 
2 methyl-2-butanol Sigma- 
Aldrich 
Kynurenic acid Sigma- 
Aldrich 
Caprofen Pfizer 
Isofluran Zoetis Magnesium 
chloride 
hexahydrate 
Merk 
Millipore 
Visidic Bausch 
Lomb 
Paraformaldehyde Serva L-(+)- Ascorbic 
acid 
Merk 
Millipore 
Iodine Animedica 
Sodium chloride Merk 
Millipore 
Tetrodotoxin Tocris 
Bioscience 
RetroBeads Lumafluor 
Inc. 
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di-Sodium hydrogen2 
phosphate dihydrate 
Merk 
Millipore 
6-cyano-7-
nitroquinoxaline-
2,3-dione 
Tocris 
Bioscience 
 
  
Sodium dihydrogen 
phosphate monohydrate 
Merk 
Millipore 
((RS)-3-(2-
Carboxypiperazin-
4-yl)-propyl-1-
phosphonic acid) 
Biolab  
 
  
Potassium chloride Merk 
Millipore 
Potassium 
gluconate 
Sigma- 
Aldrich 
 
  
Calcium chloride Merk 
Millipore 
CsCl Sigma- 
Aldrich 
 
  
Sucrose Sigma- 
Aldrich 
EGTA Sigma- 
Aldrich 
 
  
Glucose Sigma- 
Aldrich 
HEPES Sigma- 
Aldrich 
 
  
Potassium dihydrogen 
phosphate 
Merk 
Millipore 
NaGTP Sigma- 
Aldrich 
 
  
Immersion oil Zeiss 2,6-
(Dimethylphenyl 
carbamoylmethyl) 
triethylammonium 
bromide 
Tocris- 
Cookson 
 
  
Triton X-100 Roche In vivo electrophysiology 
 
  
Albumin bovine  Biomol Name Company 
 
  
Aqua poly/mount Polyscien
ces 
Baytril Bayer 
 
  
Goat serum   
 
  
 
  
Donkey serum Sigma- 
Aldrich 
 
  
 
  
Ethanol Sigma- 
Aldrich 
 
  
 
  
2-Methylbutan Roth         
                                                     
Table 2.8 continued 
MATERIALS AND METHODS 
39 
 
 
2.13 Equipment 
 
Table 2.9| List of equipment 
Immunohistochemistry 
  
Electrophysiology 
  
Stereotaxic surgery 
  
Name Company Name Company Name Company 
Cryostat Leica 
CM3050S  
Leica 
Biosystems 
Vibrotome Leica 
Biosystems 
Stereotaxic 
frame 
502300 
series 
World precision 
instruments 
Leica SP2 Leica 
Biosystems 
EPC10 
Amplifier 
HEKA Hamilton 
syringe 
7000 series 
Hamilton 
Leica MZ16 Leica 
Biosystems 
Microscope 
UCMAD3 
Olympus Drill  World precision 
instruments 
Aqua-
Poly/Mount  
Polysciences Boroscillate 
glass tubes, 
GB150F-8P 
Science 
products 
Drill bits   
In vivo electrophysiology 
  
  
 
  
  
Name Company 
  
  
Steriotaxic frame Kopf Inc. 
  
  
Rectal probe 
ATC 1000 
WPI 
    
Tungsten wires California Fine 
Wire 
    
Polymide tubes Science 
Products 
    
Connector Omnetics 
    
Amplifier HS-18 Neuralynx 
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2.14 Software 
 
Table 2.10| List of software. 
 
Immunohistochemistry Electrophysiology In vivo Electrophysiology 
Name Company Name Company Name Company 
Imaris Bitplane Igor Pro Wave Metrics MATLAB Mathworks 
ImageJ NIH Patchmaster HEKA Cheetah Data 
Acquisition 
System 
Neuralynx 
 
 
 
Acquisition 
board Digital 
Lynx 4SX 
Neuralynx 
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3. RESULTS 
Chapter 1- Role of Neuroligin 2 in Inhibitory Synaptic Function and Anxiety- Associated 
Neuronal Activation of Amygdala. 
 
Out of many genetic causes of neuropsychiatric conditions, mutations in genes regulating  synaptic 
function are increasingly linked to pathophysiology of  disorders such as autism and anxiety (Lüthi 
& Lüscher 2014; Thomas C Südhof 2008). One prominent example is the family of Neuroligins - 
adhesion proteins that maintain the function of synapses- in which more than 30 mutations were 
identified in autistic patients (Jamain et al. 2003). Previous studies described the function of 
Neuroligin 3 and Neuroligin 4 in specific synaptic networks within neural circuits underlying 
behavioral phenotypes associated with autism symptoms (Rothwell et al. 2014; Földy et al. 2013; 
Hammer et al. 2015), thus shedding light on molecular mechanisms of autism. 
 
Neuroligin 2, whose loss of function mutation was linked to schizophrenia and anxiety in humans 
(Sun et al. 2011; Parente et al. 2016) is emerging as a one of key regulators of excitation/inhibition 
balance in neural circuits underlying psychiatrically relevant behaviors, such as social behavior 
(Kohl et al. 2013; Kohl et al. 2015; Liang et al. 2015). The robust anxiety phenotype in Nlgn2 KO 
mice indicates that Nlgn2 must also play a central role in the neural circuitry underlying anxiety 
behaviors, but to date, virtually nothing is known about the function of Nlgn2 in these circuits. To 
address this problem, I investigated the molecular, cellular and physiological consequences of 
Nlgn2 KO mice in the amygdala, a brain region that has been prominently implicated in fear and 
anxiety behaviors (LeDoux 2003). For that, I characterized the behavior of Nlgn2 KOs using 
anxiety assay and then employed a “top- down” approach by first identifying a brain region and 
then a subpopulation of synapses and finally a specific neuron type affected by deletion of Nlgn2. 
Taken together, my findings support a model according to which reduced perisomatic inhibition 
at connections between Parvalbumin positive interneurons and projection neurons in BA of Nlgn2 
KO mice results in specific overactivation of these projection neurons under anxiogenic 
conditions. Thus, this study provides an important insight into possible molecular mechanisms by 
which mutations in Nlgn2 contribute to pathophysiology of anxiety and comorbid disorders.   
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3.1.1  Nlgn2 KO Causes a Robust Anxiety Phenotype 
 
Nlgn2 KO mice have previously been reported to display increased anxiety-related behaviors 
(Blundell et al. 2009) but the extent of this anxiety phenotype has been discussed controversially 
(Blundell et al., 2009, Wohr et al. 2013) To address this issue and to characterize the anxiety 
phenotype under our experimental conditions, I performed a battery of anxiety tests on Nlgn2 KO, 
Nlgn2 Het and WT littermates, including the elevated plus maze (EPM), the open field test (OFT) 
and the light/dark exploration test (LDT). Nlgn2 KO mice showed a robust anxiety phe- 
notype in all these tests (Figure 3.1.1, Figure 3.1.2), spending significantly less time and making 
fewer entries into the open arms of the EPM, the center of the OFT, and the light zone of the LDT 
(Figure 3.1.1A-C, Figure 3.1.2A). Similarly, the distance traveled in the open arms of the EPM, 
the center of the OFT, and the light zone of the LDT was significantly reduced in Nlgn2 KO mice 
(Figure 3.1.1D-F). Nlgn2 Het mice exhibited a mild anxiety phenotype only in the EPM (Figure 
3.1.1A, 3.1.1D; Figure 3.1.2A, B), with no significant differences from WT mice observed in the 
other two anxiety tests (Figure 3.1.1B, C, E, F; Figure 3.1.2). Given that Nlgn2 Het mice showed 
only a very mild behavioral phenotype, the subsequent molecular, cellular, and 
electrophysiological characterization was restricted to the comparison of WT and Nlgn2 KO mice. 
 
3.1.2 Nlgn2 KO Causes Reduced Locomotor Activity and Enhanced Freezing Specifically 
Under Anxiogenic Conditions 
 
Interestingly, the total distance traveled by Nlgn2 KO mice in the EPM and OFT was also 
significantly reduced as compared to WT and Het mice (Figure 3.1.2 B, C; this analysis could not 
be performed for the LDT for technical reasons, since the experimental setup did not permit me to 
measure activity levels in the dark zone). To determine whether this reduction in locomotor activity 
may confound the anxiety phenotype in the KO mice, I performed three additional analyses. First, 
I normalized the distance traveled in the open arms of the EPM and the center of the OFT to the 
total distance traveled in the EPM and OFT, respectively (Figure 3.1.2D, E). This analysis revealed 
that the anxiety phenotype is still highly significant even after correcting for overall activity levels. 
Second, to rule out a primary locomotor impairment, I monitored activity under basal, non-
anxiogenic conditions in a home cage setting. Under these  
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Figure 3.1.1| Anxiety phenotype and locomotor activity of Nlgn2 KO mice. 
A-C. Time spent by WT, Nlgn2 Het, and Nlgn2 KO mice in the open arms of elevated plus maze (A), 
center of the open field (B), and light zone of light dark box (C). One-way ANOVA for genotype: (A) 
F2,43 = 7.07, p <0.01, (B) F2, 43 = 37.33, p <0.0001, (C) F2, 44 = 42.73, p <0.0001.  
D-F. Distance traveled in the open arms of elevated plus maze (D), center of the open field (E), and light 
zone of light dark box (F). One-way ANOVA for genotype: (D) F2,43 = 15.83, p <0.0001; (E) F2,44 = 
35.43, p <0.0001; (F) F2,45 = 44.62, p <0.0001.  
G-H. Duration of locomotor activity (G) and distance traveled (H) in a home cage setting during 15 h of 
recording. One-way ANOVA for genotype: (G) F2,43 = 79.75, p < 0.0001; (H), F2,46 = 61.95, p <0.0001.  
I. Duration of freezing in a novel environment. One-way ANOVA for genotype: (I) F2,44 = 17.98, p < 
0.0001. Post hoc Tukey's test: * p <0.05, ** p <0.01, *** p <0.001. n = 14-18 for each genotype. All  
bars represent mean + SEM. 
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Figure 3.1.2| Horizontal activity of Nlgn2 KO mice during anxiety testing.  
A. Number of entries to open arms of elevated plus maze, center of the open field and light zone of light 
dark box. One-way ANOVA: (EPM entries) F2, 43 = 21.14, p < 0.0001; (OFT entries) F2, 45 = 44.80, p < 
0.0001; (LDT entries) F2, 46 = 28.51, p < 0.0001. 
B-C. Total distance traveled in elevated plus maze (B) and open field chamber (C). One-way ANOVA for 
genotype: (B) F2,45 = 67.41, p < 0.0001; (C) F2,45 = 31.25, p < 0.0001.  
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D, E. Ratio between distance traveled in the open arms of EPM (D) and center of the OFT (E) and respective 
total distance traveled in EPM or OFT. One- way ANOVA (EPM ratio):  F2, 45 = 3.32, p = 0.045; (OFT 
ratio) F2, 45 = 24.47, p < 0.0001.  All bars represent mean + SEM, ** p <0.01, *** p < 0.001. n = 14-18 
per genotype.   
 
 
conditions, Nlgn2 KO mice surprisingly showed an increase in locomotion (Figure 3.1.1G, H) and 
a corresponding decrease in time spent immobile (Figure 3.1.3A), while additional aspects of home 
cage activity did not differ (Figure 3.1.3). Third, based on the empirical observation that Nlgn2 
KO mice showed increased freezing during the anxiety tests, I also directly measured freezing 
behavior in a novel anxiogenic environment. Nlgn2 KO mice spent significantly more time 
freezing following first exposure to a novel chamber (Figure 3.1.1I). This increase in freezing 
likely contributes to the reduced exploratory activity, which is therefore one of the manifestations 
of the robust anxiety phenotype in Nlgn2 KO mice. 
 
3.1.3 Enhanced cFOS Activation in Basal Amygdala Neurons of Nlgn2 KO Mice Upon 
Exposure to an Anxiogenic Environment   
 
To elucidate the cellular and molecular basis for the anxiety phenotype in Nlgn2 KO mice, I 
investigated whether differential activation of neurons could be observed in various brain regions 
associated with anxiety processing, including the amygdala and prefrontal cortex (Lüthi & Lüscher 
2014; Singewald et al. 2003). To this end, I exposed WT and Nlgn2 KO mice to an anxiogenic 
environment (10 min in an open field arena) and subsequently used an immunohistochemical 
approach to assess the expression of cFOS, a marker of neuronal activity (Sagar et al. 1988).  In 
the amygdala (Figure 3.1.4A), I observed an increase in overall cFOS activation of basal amygdala 
(BA) neurons in Nlgn2 KO mice, which was significant in the anterior basal region (Figure 
3.1.4B), but not in lateral, posterior, or ventromedial regions (Figure 3.1.4C-E). This increase was 
triggered by the anxiogenic situation, since cFOS expression under basal conditions did not 
significantly differ between WT and Nlgn2 KO mice (Figure 3.1.6). In contrast, we observed no 
genotype difference in cFOS immunoreactivity in two areas of prefrontal cortex, the infralimbic 
and prelimbic cortices (Figure 3.1.5).  These findings indicate that the BA is one of the brain  
 
RESULTS 
 
46 
 
 
Figure 3.1.3| Activity of Nlgn2 KO mice in home cage setting.  
(A-D) Duration of immobility (A), climbing (B), grooming (C), and circling behavior (D) of Nlgn2 KOs, 
Nlgn2 Hets, and WT mice during 15 h of recording. One-way ANOVA for genotype: (A) F2,44 = 98.12, p < 
0.0001; (B) F2,44 < 1; (C) F2,44 < 1; (D) F2,44 < 1. All bars represent mean + SEM, *** p < 0.001. n = 14-18 
per genotype. 
 
 
regions involved in the anxiety phenotype of Nlgn2 KO mice, and I therefore focused our further 
analyses on this region. 
 
3.1.4 Nlgn2 is Localized to Inhibitory Synapses in the Basal Amygdala 
 
To investigate the molecular mechanisms underlying the increased anxiety-triggered activation of 
BA neurons in Nlgn2 KOs, we first assessed the expression pattern of Nlgn2 in the amygdala of 
WT mice. We found that Nlgn2 is highly expressed in the basal nucleus but not in the central  
nucleus of the amygdala (Figure 3.1.7A). To characterize which synapses contain Nlgn2 in this 
region we performed double labeling of Nlgn2 with PSD-95, a marker of excitatory synapses, and 
with gephyrin, a marker of inhibitory synapses. Our data show that Nlgn2 colocalizes with 
gephyrin (Figure 3.1.7B; Pearson's correlation coefficient = 0.62) but not with PSD-95 (Figure 
3.1.7C; Pearson's correlation coefficient = 0.01), consistent with previous reports on Nlgn2 
distribution in other brain regions, including retina (Hoon et al. 2009) and hippocampus 
(Poulopoulos et al. 2009; Varoqueaux et al. 2006). Approximately 76% of Nlgn2 puncta were 
colocalized with gephyrin, indicating that Nlgn2 is localized primarily to inhibitory synapses in 
BA. Interestingly, 78% of gephyrin puncta were also positive for Nlgn2, indicating that Nlgn2 is 
present at the majority of inhibitory synapses in BA.  
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Figure 3.1.4| Anxiety-induced cFOS expression in basolateral amygdala of Nlgn2 KO mice.  
A. Low magnification photomicrographs of cFOS labeled basolateral amygdala indicate the regions 
included in the analysis. Scale bar, 100 µm.  
B-E. Quantification of cFOS positive cells in anterior BA (B), lateral amygdala (C), posterior BA (D), and 
basolateral ventromedial amygdala (E) in WT and Nlgn2 KO mice. cFOS expression was triggered by 
exposure to novel environment. 
F. Representative photomicrographs of cFOS expression in anterior BA of WT and Nlgn2 KO mice after 
exposure to novel environment. Scale bar, 20 μm. Paired Student’s t-test: * p < 0.05. n = 6 for each genotype 
in figures B, D and E, n = 5 for each genotype in figure C. All bars represent means + SEM. 
 
Figure 3.1.5| Anxiety induced cFOS expression in cortical components of anxiety circuitry. 
A-B.  Quantification of cFOS positive cells in prelimbic (A) and infralimbic (B) regions of medial prefrontal 
cortex. All bars represent means + SEM. n = 5 for each genotype. 
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Figure 3.1.6| Basal cFOS expression in anterior BA of WT and Nlgn2 KO mice.  
A-B. Photomicrographs of cFOS expression in basal amygdala (A) and quantification of cFOS positive 
cells (B) in anterior BA of mice that were taken from their home cages. All bars represent mean + SEM, n 
= 5.    
 
 
 
 
 
Figure 3.1.7| Nlgn2 localization in the amygdala.  
A. Immunostaining shows that Nlgn2 is highly expressed in the basal and lateral nuclei of the amygdala, 
while its expression in the CeA is low. Scale bar, 100 μm.  
B-C. Colocalization of Nlgn2 with gephyrin, a marker of inhibitory synapses (B), and PSD- 95, a marker 
of excitatory synapses (C). Scale bar, 2 μm. 
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3.1.5 Nlgn2 KO Perturbs the Composition of Perisomatic Postsynaptic Sites in the Basal 
Amygdala 
 
Given the localization pattern of Nlgn2 at inhibitory synapses, I next investigated whether the 
loss of Nlgn2 affects the structure of inhibitory synapses in the BA by quantifying the number and 
intensity of gephyrin puncta. The overall gephyrin intensity was not altered upon Nlgn2 loss 
(Figure 3.1.8A-B). However, a specific analysis of perisomatic regions (Figure 3.1.8C-D) revealed 
a significant reduction in the number, size, and intensity of gephyrin puncta in Nlgn2 KOs (Figure 
3.1.8E-G). To investigate whether this reduction is caused by a decrease in the total number of 
inhibitory synapses, I stained for the vesicular inhibitory amino acid transporter (VIAAT), a 
marker of inhibitory presynaptic terminals (Figure 3.1.9A), and found that the number and size of 
perisomatic VIAAT puncta are not altered upon Nlgn2 deletion (Figure 3.1.9B-C). To confirm this 
finding, I quantified the number of parvalbumin (PV) puncta in the BA (Figure 3.1.9D). PV- 
positive interneurons are the major source of perisomatic synapses in BA (Muller et al. 2006; 
Spampanato et al. 2011), and PV puncta therefore specifically represent perisomatic inhibitory 
presynaptic sites. The number and intensity of PV-positive puncta was not altered in Nlgn2 KO 
mice (Figure 3.1.9E-F). Taken together, these findings imply that Nlgn2 deletion does not result 
in a decrease in overall inhibitory synapse number in BA, but instead primarily affects the 
molecular composition of perisomatic inhibitory postsynaptic sites. 
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Figure 3.1.8| Localization and expression levels of gephyrin in BA of Nlgn2 KO mice. 
A. Photomicrographs show overall gephyrin distribution in BA of WT and Nlgn2 KO mice. Scale bar, 10 
μm. 
B. Mean fluorescence intensity of overall gephyrin immunostaining. n = 6 for each genotype. 
C-D. High magnification photomicrographs show perisomatic gephyrin localization in BA of WT and 
Nlgn2 KO (C). The perisomatic area is indicated on a thresholded image (D). Scale bar, 2 μm.  
E-G. Mean number per cell perimeter (E), mean area (F), and mean intensity (G) of perisomatic gephyrin 
puncta in BA. n = 8 for each genotype. Paired, two-tailed Student's t-test: * p < 0.05, ** p < 0.01. All bars 
represent mean + SEM 
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Figure 3.1.9| Localization and expression levels of presynaptic inhibitory markers in BA of Nlgn2 
KO mice.  
A. Photomicrographs show perisomatic VIAAT expression in BA of WT and Nlgn2 KO mice. Scale bar, 
2 μm. 
B-C. Mean number per cell perimeter (B) and mean area (C) of perisomatic VIAAT puncta.  
D. Photomicrographs show overall localization and expression levels of PV in anterior BA of WT and 
Nlgn2 KO mice. Scale bar, 20 μm.  
E-F. Total number (E) and mean intensity (F) of PV puncta in analyzed area of BA. n = 6 for both 
genotypes. All bars represent mean + SEM. 
 
 
3.1.6 Nlgn2 KO Impairs Inhibitory Synaptic Transmission in the Basal Amygdala 
 
To assess whether deletion of Nlgn2 alters synaptic transmission, Paolo Botta (Friedrich Miescher 
Institute for Biomedical Research, Basel, Switzerland) measured miniature inhibitory postsynaptic 
currents (mIPSCs) in the BA and central amygdala (CeA, Figure 3.1.10). A pronounced reduction 
in mIPSC frequency but not amplitude (Figure 3.1.10 E-F) was observed in BA of Nlgn2 KO mice, 
while mIPSC kinetics were not significantly altered (rise time: WT = 1.40 ms, KO = 1.57 ms, p = 
0.13; decay time: WT = 4.14 ms, KO = 2.87 ms, p = 0.09). In CEA, no changes were observed in 
mIPSC frequency or amplitude (Figure 3.1.10 G-H).  
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Figure 3.1.10| Effect of Nlgn2 deletion on inhibitory synaptic transmission in BA and CeA.  
A-B. Schematic diagram showing the location of recordings and representative miniature IPSCs in BA (A) 
and CeA (B) of WT (black) and Nlgn2 KO mice (grey).  
C-D. Sample traces from BA (C) and CeA (D) of WT and Nlgn2 KO mice. 
E-F. Average frequency (E) and amplitude (F) of mIPSCs in BA of WT (black) and Nlgn2 KO mice 
(white). 
G, H. Average frequency (G) and amplitude (H) of mIPSCs in CeA of WT (black) and Nlgn2 KO mice 
(white). n = 14-15 for both genotypes. Unpaired, two-tailed Student's t-test: *** p < 0.001. All bars 
represent mean + SEM. 
 
 
* Experiments performed by Paolo Botta. 
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3.1.7 Nlgn2 KO has Differential Effects on Anxiety-Associated Activation of Glutamatergic 
and GABAergic Neurons in the Basal Amygdala 
 
BA is a cortex-like structure that contains both glutamatergic projection neurons and local 
inhibitory interneurons (Ehrlich et al., 2009; Sah et al., 2003), each of which play a distinct role 
in the acquisition and expression of fear- and anxiety-related behavioral outputs (Tye et al. 2011; 
Namburi et al. 2015; Wolff et al. 2014). To understand the circuitry underlying the behavioral 
phenotype in Nlgn2 KO mice, it was therefore essential to investigate the influence of Nlgn2 
deletion on distinct amygdala cell types. To dissect the anxiety-induced activation pattern of 
several types of neurons that have been previously linked to fear behaviors (Wolff et al., 2013) I 
performed double labeling of cFOS and CaMKII (as a marker for glutamatergic projection 
neurons), PV, or somatostatin (SOM) in WT and Nlgn2 KO animals that had been exposed to 
anxiogenic conditions. I quantified both the total number and the cFOS-positive percentage of 
each type of neuron. I found that Nlgn2 KO mice exhibit enhanced activation of projection 
neurons in BA (Figure 3.1.11A, E), with no change in the total number of projection neurons 
(Figure 3.1.11D). In contrast, the total number of PV-positive cells was significantly increased in 
Nlgn2 KO mice (Figure 3.1.11B, F), without a significant change in the percentage of PV-positive 
cells that showed cFOS immunoreactivity (Figure 3.1.11G). Nlgn2 deletion did not have an effect 
on SOM-positive interneurons, as both their total number and their cFOS-positive fraction were 
unaltered in Nlgn2 KO mice (Figure 3.1.11C, H, I). These data indicate that Nlgn2 deletion 
impacts specific types of inhibitory synapses in BA in a manner that leads to an increased anxiety 
phenotype of the KO mice. In addition, the enhanced PV immunoreactivity indicates a perturbed 
development, maintenance, or homeostasis of this inhibitory neuronal network in Nlgn2 KO mice.   
 
3.1.8 Summary and Conclusions 
 
Using a combination of behavior assessment and cFOS activation assay, I show that Nlgn2 deletion 
in mice leads to robust anxiety, which is accompanied by enhanced cFOS expression of anterior 
basal amygdala. In search for molecular mechanism of this activity upregulation I use quantitative 
morphological analysis and electrophysiology and show that Nlgn2 is localized exclusively at  
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Figure 3.1.11| Effect of Nlgn2 deletion on cellular components of the anxiety circuitry in BA. A-C. 
Photomicrographs of anterior BA in WT mice and Nlgn2 KO mice following exposure to stress. The slices 
were double immunolabeled for cFOS and CaMKII (A), cFOS and PV (B), or cFOS and SOM (C). Scale 
bar, 50 μm.  
D-I. Number of CaMKII (D), PV (F), and SOM (H) positive cells and percentage of CaMKII (E), PV (G), 
and SOM (I) positive cells that express cFOS following exposure to stress. For each genotype, n = 7 for 
CaMKII/cFOS analysis, n = 6 for analysis of inhibitory markers. Paired Student's t-test: * p < 0.05, ** p < 
0.01. All bars represent means + SEM. 
 
inhibitory synapses and that Nlgn2 deletion does not affect the total number of inhibitory synapses 
but leads to alterations in the structure and function of perisomatic inhibitory synapses in the basal 
amygdala. By dissecting the cFOS expression pattern to distinct types of neurons, I show that 
CAMKII- positive glutamatergic projection neurons show increased induction of cFOS in Nlgn2 
KO mice, while inhibitory activation of inhibitory Parvalbumin and Somatostatin neurons remains 
unaltered.   
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Taken together my findings suggest that deletion of Neuroligin2 specifically affects inhibitory 
transmission at the soma of glutamatergic neurons in basal amygdala, thus upregulating the 
excitatory output of basal amygdala under anxiogenic conditions. As enhanced output of basal 
amygdala leads to anxiety- like behavior in mice (Tye et al. 2011), my findings offer a plausible  
molecular mechanism of increased anxiety- like behavior of Nlgn2 KOs. Further studies will be 
needed to elucidate the role of Nlgn2 in downstream components of anxiety processing circuitry 
that were not addressed here (such as central amygdala) and find possible synaptic partners that 
compensate for lack of Nlgn2 at synapses that appear unaffected by Nlgn2 deletion. These studies 
may provide essential insights into underlying molecular mechanisms and potential drug targets 
for the treatment of anxiety and co morbid disorders. 
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Chapter 2 – Role of IgSF9b in Regulation of Anxiety Phenotype of Nlgn2 KO 
 
One of the major bottlenecks in characterizing the molecular basis of neuropsychiatric disorders 
is the complex relationship between genetic risk factors and pathological behaviors. Various 
mutations may lead to similar behavioral abnormalities despite producing distinct molecular 
deficits. On the other hand, a variety of pathological phenotypes with variable severity may all be 
linked to the same mutation (Zoghbi 2003; Bourgeron 2016). It is therefore clear that the 
contribution of single gene mutations to pathophysiology cannot be inferred from their impact on 
protein function, but rather from their collective impact on neural pathways that regulate behavior.  
 
One such pathway linking several mutations to anxiety-related phenotypes is the inhibitory 
synapse in basal amygdala (Vislay et al. 2013; Müller et al. 2015). Consistent with this notion, my 
previous findings show that Nlgn2 KO produces molecular and functional deficits of inhibitory 
synapses in basal amygdala and increases anxiety- like behavior in mice. However, to fully 
characterize the role of Nlgn2 in anxiety, it is necessary to understand the synaptic interactions 
that shape the effect of Nlgn2 on anxiety related behavior.  
 
One molecule that has been reported to act in a complex with Nlgn2 is the newly identified cell 
adhesion molecule IgSF9b. In cell cultures, Nlgn2 and IgSF9b have been shown to bind to the 
same synaptic scaffold protein and to have a similar mode of action at inhibitory synapses (Woo 
et al. 2013). However, nothing is known about the function of IgSF9b or the interplay between 
IgSF9b and Nlgn2 in vivo, and particularly in the circuitry underlying anxiety or other 
psychiatrically related behaviors. Given their similar effects in cell cultures, I hypothesized that 
IgSF9b may modulate the function of Nlgn2 at inhibitory synapses in basal amygdala and 
exacerbate their anxiety related phenotype. To address this question, I combined behavioral 
testing, cFOS activation assay, neuronal tracing, quantitative immunohistochemistry and in vitro 
and in vivo electrophysiology in WT, Nlgn2 KO, IgSF9b KO and double KO mice. I showed that 
IgSF9b deletion rescues the anxiety-related phenotype of Nlgn2 KOs by modulating anxiety-
associated activation and rescuing the deficit in inhibitory transmission of centromedial amygdala, 
the downstream target of basal amygdala. My findings identify a novel neural substrate of anxiety 
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in centromedial amygdala and establish a novel modulator of Nlgn2 function in anxiety processing, 
thus expanding the current knowledge on circuit and molecular mechanisms of anxiety. 
 
Part 1- Characterization of the Anxiety Processing Circuit in Nlgn2 KOs, IgSF9b KOs and 
double KOs. 
 
3.2.1 IgSF9b KO Rescues the Anxiety Phenotype of Nlgn2 KOs 
 
IgSF9b has been shown to localize to inhibitory synapses and reduce inhibitory transmission in 
cell cultures (Woo et al. 2013), suggesting that in vivo deletion of IgSF9b may exacerbate the 
inhibitory deficit and hence the anxiety phenotype in Nlgn2 KOs. To test this, I performed an open 
field test (OFT) on Nlgn2 KO, IgSF9b KO, double Nlgn2 IgSF9b KO and WT mice. Nlgn2 KO 
show a robust anxiety phenotype, making less entries and exploring the center significantly less 
than WT mice (Figure 3.2.1A-D), consistent with our previous findings (with an exception that 
albeit a strong trend, Nlgn2 KO did not spend significantly less time in the center of the open field 
than WTs (Figure 3.2.1D)). Surprisingly, IgSF9b KO show a significant increase in number of  
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Figure 3.2.1| Anxiety phenotype and locomotor activity of Nlgn2 KO, IgSF9b KO and double KO 
mice in the open field chamber. 
A. Representative tracks made by WT, Nlgn2 KO, IgSF9b KO and double KO during open field test.  Red 
squares delineate the zone defined as a center of the open field. 
B-D. Activity in the center zone of the open field chamber: total number of entries to the center (B), ratio 
between distance travelled in the center and total distance travelled in the open field (C) and time spent in 
the center (D). Two-way ANOVA: (B) Main effect of Nlgn2 KO, F3,39 = 94, p < 0.0001; main effect of 
IgSF9b KO, F3,39 = 91.4, p < 0.0001.  (C) Main effect of Nlgn2 KO, F3,41 = 15.92, p < 0.0001; main effect 
of IgSF9b KO, F3,39 = 15.34, p < 0.0001.  (D) Main effect of Nlgn2 KO, F3,42 = 7.95, p = 0.0075; main effect 
of IgSF9b KO, F3,42 = 27.68, p < 0.0001. No significant interaction between genotypes. 
E. Total distance travelled in the open field chamber. Two-way ANOVA: Main effect of Nlgn2 KO, F3,41 
= 51.86, p < 0.0001; main effect of IgSF9b KO, F3,41 = 22.28, p < 0.0001. No significant interaction between 
genotypes. Post hoc one-way ANOVA with Bonferroni’s correction: * p < 0.05, ** p< 0.01, *** p < 0.001 
compared to WT; # p < 0.05, ## p< 0.01, ### p < 0.001 compared to double KO. n = 10-11 for each 
genotype. All bars represent mean + SEM. 
 
 
entries and time in the center of the open field (Figure 3.2.1A-B, D). Moreover, there is a complete 
rescue of the anxiety phenotype in double KO mice, which made similar number of entries, 
traveled the same normalized distance and spend same time in the center of the open field as WT 
mice (Figure 3.2.1A-D). While total distance traveled during OFT was significantly lower in 
Nlgn2 KO and significantly higher in IgSF9b KO compared to WT and double KOs (Figure 
3.2.1E), this alteration of exploratory activity did not confound the anxiety phenotype, as evident 
in normalized activity in the center of the open (Figure 3.2.1C), which is significantly reduced in 
Nlgn2 KO and slightly but not significantly increased in IgSF9b KO. Taken together, these 
findings show that the prominent anxiety phenotype of Nlgn2 KOs may be rescued by deletion of 
IgSF9b, and that IgSF9b KO may suppress anxiety related processing in mice. 
 
Based on empirical observation of Nlgn2 KO mice behavior in the OF, I hypothesized that the 
definition of the size of the center zone may mask the full extent of their anxiety- related 
phenotype. To establish whether Nlgn2 KO mice demonstrate anxiety- related behavior in more 
peripheral areas of the open field, I reanalyzed the behavioral data with respect to an intermediate 
zone (IZ), which I defined as a zone between the center and the area adjacent to the walls of the 
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Figure 3.2.2| Anxiety phenotype of Nlgn2 KO, IgSF9b KO and double KO mice in the intermediate 
zone and extended center of the open field. 
A. Intermediate zone between the center of the OF and an area in immediate proximity to the walls (between 
two red squares). 
B-D. Activity in the intermediate zone of the open field chamber: total number of entries to the center (B), 
ratio between distance travelled in the center and total distancet travelled in the open field (C) and time 
spent in the center (D). Two-way ANOVA: (B) Main effect of Nlgn2 KO, F3,40 = 41.19, p < 0.0001; main 
effect of IgSF9b KO, F3,40 = 30.10, p < 0.0001.  (C) Main effect of Nlgn2 KO, F3,39 = 6.34, p = 0.016; main 
effect of IgSF9b KO, F3,39 = 22.05, p = 0.0008.  (D) Main effect of Nlgn2 KO, F3,38 = 17.288, p = 0.0002; 
main effect of IgSF9b KO, F3,38 = 10.03, p = 0.003. No significant interaction between genotypes. 
E. Redefined extended center zone that covers all the area of the open field chamber that is not in immediate 
proximity to the walls (red square). 
F-H. Activity in the extended center zone of the open field chamber: total number of entries to the center 
(F), ratio between distance travelled in the center and total distancet travelled in the open field (G) and time 
spent in the center (H). Two-way ANOVA: (B) Main effect of Nlgn2 KO, F3,41 = 30.73, p < 0.0001; main 
effect of IgSF9b KO, F3,41 = 37.25, p < 0.0001.  (C) Main effect of Nlgn2 KO, F3,41 = 20.04, p < 0.0001; 
main effect of IgSF9b KO, F3,39 = 13.34, p = 0.0008.  (D) Main effect of Nlgn2 KO, F3,42 = 13.13, p = 
0.0008; main effect of IgSF9b KO, F3,42 = 18.18, p = 0.0001. No significant interaction between genotypes. 
RESULTS 
 
60 
 
Post hoc one-way ANOVA with Bonferroni’s correction: * p < 0.05, ** p< 0.01, *** p < 0.001 compared 
to WT; ## p< 0.01, ### p < 0.001 compared to double KO. n = 10-11 for each genotype. All bars represent 
mean + SEM. 
 
 
open field chamber (Figure 3.2.2A). Nlgn2 KO mice show strong thigmotaxis by making fewer 
entries and spending less time in the areas that are not adjacent to the walls of the open field. The 
extent of exploration of the IZ by double KO mice is again strikingly similar to that of WT mice 
(Figure 3.2.2B-D). As anxiety-related behavior of Nlgn2 KO and the rescue in double KO mice 
are evident both in IZ and the center of the open field, I merged IZ and the center zone into 
“extended center” (Figure 3.2.2E) and combined the behavioral data obtained from both zones. 
Anxiety- related phenotype of Nlgn2 KO mice is more robust in the extended center than in the 
initially used center of the open field (Figure 3.2.2F-H), suggesting that the previous definition of 
the center masked the full extent of the anxiety phenotype of Nlgn2 KOs. Therefore, I applied an 
extended center for the behavioral analysis of the consecutive experiments. 
 
Finally, as all the previous experiments were conducted on male mice, I tested anxiety- related 
phenotypes of female Nlgn2 KO, IgSF9b KO and double KO mice. The phenotypes of females 
were similar to males (Figure 3.2.3A-C), demonstrating that sex does not modulate the effect of 
Nlgn2 KO and IgSF9b KO on anxiety. 
 
3.2.2 IgSF9b KO Rescues the Anxiety Associated Overactivation of Centromedial, but not 
Basal, Amygdala in Nlgn2 KO Mice 
 
To investigate the mechanism of anxiety rescue in double KOs, I first determined whether deletion 
of IgSF9b alters the anxiety- associated upregulation of basal amygdala in Nlgn2 KOs, and/or of 
adjacent regions that network with basal amygdala to mediate anxiety- related behavior, including  
lateral and central amygdala (Iwata et al. 1986; LeDoux et al. 1988; Tye et al. 2011) (Figure 
3.2.4A). To this end, I exposed WTs, Nlgn2 KOs, IgSF9b KOs and double KOs to a novel 
environment (open field arena) and subsequently assessed cFOS activation of basal (BA), 
centromedial (CeM), lateral (LA) and centrolateral (CeL) amygdala. While the anxiety associated 
cFOS activation of LA and CeL is not altered in either Nlgn2 KO or IgSF9b KO (Figure 3.2.4E- 
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Figure 3.2.3| Anxiety phenotype of female Nlgn2 KO, IgSF9b KO and double KO mice in the open 
field chamber. 
A-C. Total number of entries to the center (A), ratio between distance travelled in the center and total 
distance travelled in the open field (B) and time spent in the center (C). Two-way ANOVA: (A) Main effect 
of Nlgn2 KO, F3,49 = 58.73, p < 0.0001; main effect of IgSF9b KO, F3,49 = 45.66, p < 0.0001.  (B) Main 
effect of Nlgn2 KO, F3,48 = 27.88, p < 0.0001; main effect of IgSF9b KO, F3,48 = 13.02, p= 0.0007.  (C) 
Main effect of Nlgn2 KO, F3,46 = 30.47, p < 0.0001; main effect of IgSF9b KO, F3,46 = 54.27, p < 0.0001. 
No significant interaction between genotypes. 
Post hoc one-way ANOVA with Bonferroni’s correction: * p < 0.05, ** p< 0.01, *** p < 0.001 compared 
to WT; # p < 0.05, ## p< 0.01, ### p < 0.001 compared to double KO. n = 10-11 for each genotype. All 
bars represent mean + SEM. 
 
 
F), all four genotypes show differential cFOS expression pattern in BA and CeM (Figure 3.2.4C-
D). Nlgn2 deletion results upregulation of cFOS expression in BA (Figure 3.2.4C) and particularly 
robustly in CeM (Figure 3.2.4D). Deletion of IgSF9b alone does not significantly alter the cFOS 
expression in any amygdala region, although there is a trend towards increase in BA (paired ttest, 
p = 0.057; Figure 3.2.4C-D). Strikingly, IgSF9b KO in Nlgn2 KOs robustly increases cFOS 
activation of BA (Figure 3.2.4C) and suppresses cFOS activation of CeM (Figure 3.2.4D). Taken 
together, these findings demonstrate that IgSF9b KO modulates the effect of Nlgn2 KO on anxiety 
associated activation of BA-CeM circuit. The following experiments aimed to elucidate the 
mechanism of this modulation. 
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Figure 3.2.4| Anxiety-associated cFOS expression in distinct nuclei of amygdala in WT, Nlgn2 KO, 
IgSF9b KO and double KO mice.  
A. Schematic representation of anxiety processing network in the amygdala. 
B. Representative photomicrographs of cFOS expression in basal and centromedial amygdala.  Scale bar, 
50 m. Here and below, cFOS expression was triggered by exposure to novel environment. 
C-F. Total number of cFOS positive cells in basal (C), centromedial (D), lateral (E) and centrolateral (F) 
amygdala. Two-way ANOVA: (C) Main effect of Nlgn2 KO, F3,28 = 7.58, p = 0.01; main effect of IgSF9b 
KO, F3,28 = 4.58, p = 0.041.  (D) Main effect of Nlgn2 KO, F3,26 = 9.47, p = 0.006; main effect of IgSF9b 
KO, F3,26 = 0.044. (E, F) No significant main effect of the genotype.  No significant interaction between 
genotypes. Post hoc paired ttests: * p < 0.05, ** p< 0.01 compared to WT; # p < 0.05, ## p< 0.01 compared 
to double KO. n = 8 (C), n = 6 (D), n = 5 (E, F) for each genotype. All bars represent mean + SEM. 
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3.2.3 IgSF9b KO Upregulates the Anxiety Associated Activation of Parvalbumin Neurons in 
Basal Amygdala 
 
IgSF9b KO may suppress the anxiety-associated activation of CeM in Nlgn2 KOs either by 
decreasing excitatory output from BA to CeM or by locally downregulating neural firing in CeM, 
or by both mechanisms. I first addressed the first possibility and investigated the effect of IgSF9b  
deletion on inhibitory circuitry in BA, specifically on anxiety-associated activation of interneurons 
that inhibit glutamatergic projection neurons during fear- related processing in BA, such as 
Parvalbumin (PV) and Somatostatin (SOM) (Wolff et al. 2014; summarized in Figure 5A).  To 
this end, I performed double labeling of cFOS and PV or SOM in Nlgn2 KOs, IgSF9b KOs, double 
KOs and WTs after their exposure to an anxiogenic environment. IgSF9b KO enhances the 
activation of PV neurons in BA both in single IgSF9b KOs and, more robustly, in double KOs 
(Figure 3.2.5B-C), and does not alter the activation of SOM neurons (Figure 3.2.5F). The total 
number of PV neurons was increased in Nlgn2 KOs, as shown previously, but did not significantly 
differ between WT, IgSF9b KOs and double KOs (Figure 3.2.5D). This finding suggests that 
deletion of IgSF9b enhances the activation of PV network that may decrease the excitatory output 
of glutamatergic neurons during anxiety- related processing. 
 
3.2.4 IgSF9b KO Does Not Downregulate the Excitatory Output from Basal Amygdala to 
Centromedial Amygdala in Nlgn2 KOs 
 
Next I determined whether Nlgn2 KO or IgSF9b KO modulate anxiety-associated activation of 
glutamatergic neurons in BA that project to CeM. To label CeM projectors, which do not express 
distinctive cellular markers and are intermingled with other glutamatergic neurons in BA (Namburi 
et al. 2015), I established a retrograde tracing technique that allows the delivery of fluorescent 
beads injected to CeM to the cell bodies of neurons in BA that project to CeM (Figure 3.2.6A-C). 
A week after the injection of beads into CeM, Nlgn2 KOs, IgSF9b KOs, double KOs and WTs 
were exposed to novel environment followed by cFOS labeling of BA. While more data points 
must be added to reach statistical significance, there is a robust trend towards increase in number 
of beads- labeled neurons that express cFOS in all three genotypes, that is particularly robust in  
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Figure 3.2.5| Effect of IgSF9b deletion on anxiety- associated activation of inhibitory network in basal 
amygdala in WT and Nlgn2 KO mice. 
A. Schematic representation of neuronal components of local inhibitory network in basal amygdala. 
B, E. Photomicrographs of cFOS and Parvalbumin colocalization in basal amygdala of WT, Nlgn2 KO, 
IgSF9b KO and double KO (B) and representative photomicrograph of cFOS and Somatostatin 
colocalization in basal amygdala of WT (E). Arrows indicate cFOS positive Parvalbumin neurons. Here 
and below cFOS expression was triggered by exposure to novel environment.  Scale bar, 50 m. 
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C-D. Total number of Parvalbumin neurons (C) and percentage of Parvalbumin neurons that express cFOS 
out of total number of Parvalbumin neurons (D) in basal amygdala. Two-way ANOVA: (C) Main effect of 
Nlgn2 KO, F3,28 = 3.5, p = 0.07 (a trend), no significant main effect of IgSF9b KO.   (D) Main effect of 
Nlgn2 KO, F3,28 = 7.17, p = 0.012; main effect of IgSF9b KO, F3,28= 17.66, p = 0.0002.  No significant 
interaction between genotypes. Post hoc paired ttests: * p < 0.05, ** p< 0.01, compared to WT; # p < 0.05, 
## p< 0.01, compared to double KO. n = 8 for each genotype.  
F. Percentage of Somatostatin neurons that express cFOS out of total number of Somatostatin neurons in 
basal amygdala. No significant main effect of the genotype.  No significant interaction between genotypes. 
n = 7 for each genotype. All bars represent mean + SEM. 
 
 
Nlgn2 KO and double KO (Figure 3.2.6D-E). This demonstrates that Nlgn2 KO upregulates 
anxiety associated activation of BA excitatory output to CeM, which is consistent with increased 
cFOS expression in CeM of Nlgn2 KOs. Surprisingly, although IgSF9b deletion upregulates 
inhibitory PV network in BA, it does not suppress the activation of CeM projectors in Nlgn2 KOs, 
indicating that rescue of anxiety associated CeM activation in double KOs is mediated downstream 
of BA by a local mechanism in CeM.  
 
3.2.5 Centromedial Amygdala Mediates Anxiety Related Processing In Vivo 
 
Higher cFOS activation of CeM in “anxious” Nlgn2 KO mice compared to “non-anxious” double 
KO mice indicates that neural activity in CeM may be associated with anxiety- related behavior, 
and that IgSF9b KO may modulate this activity to rescue the anxiety- related phenotype of Nlgn2 
KO mice. Therefore, I hypothesized that the extent of activation of CeM during exploration of the 
OF correlates with the extent of avoidance of the center zone, and that neural activity in CeM 
differentially encodes “safe” (periphery) and “danger” (center) zones across genotypes.  As cFOS 
activation assay does not provide with temporal resolution necessary to measure neural activity in 
different compartments of the open field, I sought to assess neural activity of CeM while the mice 
explore different compartments of OF by recording local field potential (LFP) in CeM in vivo. The 
recording and data analysis was performed by Dr. Hugo Cruces- Solis at the Department of 
Molecular Neurobiology, Max Planck Institute for Experimental Medicine. 
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Figure 3.2.6| Effect of Nlgn2 and IgSF9b KO on anxiety- associated activation of glutamatergic  
neurons in basal amygdala that project to centromedial amygdala.  
A.  Schematic representation of delivery of retro beads into basal amygdala following injection of retro 
beads to centromedial nucleus.  
B-C. Photomicrograph showing the injection site of retro beads in the centromedial amygdala (B) and high 
magnification photomicrograph showing the expression of red beads in the cell body (delineated with white 
circle) of a neuron in basal amygdala following migration of the beads from centromedial amygdala (C). 
Scale bar, 200 m, 2 m. 
D. Photomicrographs of cFOS and retro beads colocalization in basal amygdala of WT, Nlgn2 KO, 
IgSF9b KO and double KO mice. Arrows indicate cFOS positive neuron bodies filled with retro beads. 
Scale bar, 50 µm.     
E. Percentage of beads- containing neurons that express cFOS out of total number of beads- containing 
neurons in basal amygdala, relative to the baseline. The baseline was set as average percentage in WT at 
100%.  n = 3-4. All bars represent mean + SEM. 
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Experiment performed by Dr. Hugo Cruces Solis 
 
Figure 3.2.7| Effect of exposure to the open field on CeM neural activity in WT, Nlgn2 KO, IgSF9b 
KO and double KO. 
A. Photomicrograph showing the recording site in CeM (yellow mark). 
B. Average power spectra of CeM LFP obtained in the home cage (dashed line) and during 10 minutes of 
OF exploration (solid line).   
 
 
One week after the implantation of the electrodes in the CeM (Figure 3.2.7A), LFPs were recorded 
in the home cage and during 15 minutes of OFT in Nlgn2 KO, IgSF9b KO, double KO and WT 
mice. First, we tested whether exposure to novel environment increases neural activation in CeM 
in all genotypes by comparing the LFPs in home cage vs LFPs in OFT. Power spectra analysis of 
the LFPs revealed that exposure to the OF chamber robustly increases the power across the 
frequency range analyzed (Figure 3.2.7B) in WT, Nlgn2 KO, IgSF9b KO and double KOs. This 
OF- induced increase demonstrates that CeM is activated by anxiogenic conditions. 
 
3.2.6 IgSF9b KO Rescues the Enhanced Anxiety Associated Activation of CeM in Nlgn2 KOs 
 
Next, we tested whether deletion of Nlgn2 and/or IgSF9b differentially modulates neural activity 
in CeM during exploration of the OFT.  To this end, we analyzed separately the recording obtained 
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Figure 3.2.8| CeM activity during exploration of periphery and center of the OF. 
A-B. Average power spectra of CeM LFP in the center (A) and in the periphery of the OF (B). n = 6 for 
WT and IgSF9b KO, n = 4 for Nlgn2 KO and n = 3 for double KO.  
 
 
while mice were exploring the periphery vs the center of the OF. Nlgn2 KO demonstrate a slight 
increase in LFP of CeM during exploration of the center of the OF compared to IgSF9b KOs, 
double KOs and WTs (Figure 3.2.8A), while the LFP during exploration of the periphery is similar 
in all genotypes (Figure 3.2.8B). To further investigate this center- specific increase in LFP power 
of Nlgn2 KO, we analyzed the transitions as the mice approached and explored the center. This 
analysis is typically used to assess dynamic change in neural activity during exploration of the 
open field (Likhtik et al. 2013; Stujenske et al. 2014). For each transition, we compared the LFP 
power relative to the baseline (average power of LFP in the periphery) for each time point and 
plotted the magnitude of change in average LFP power across all trials. This analysis revealed that  
Nlgn2 deletion robustly increases the power of LFP during exploration of the center of OF across 
all frequency ranges (Figure 3.2.9A). 
 
Strikingly, this increase is rescued in the double KO at high gamma frequency range (70- 120 Hz), 
as evident in direct comparison of change in high gamma LFP in all genotypes (Figure 3.2.9B). 
To quantify the magnitude of center- induced change of high gamma band, we averaged the high 
gamma power across each trial. We observed > 10- fold center- induced increase in gamma 
frequency power in Nlgn2 KO mice, as well as a small increase in double KO that corresponded 
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Experiment performed by Dr. Hugo Cruces Solis 
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Figure 3.2.9| Effect of Nlgn2 KO on CeM activity during center-periphery transitions and correlation 
of CeM activity to anxiety- like behavior. 
A. Normalized power change during transitions from periphery to the center, averaged across transitions 
and plotted as a function of time (time point in which the mouse is closest to the center is designated as 
zero, 5 s of data on both sides of zero are shown). Baseline defined as average LFP power obtained during 
first three seconds of transition to the center.  
B-C. Normalized 70-120 Hz power change during 10 seconds of center-periphery transition (B) and its 
mean (taken from 52 data points for each mouse) (C). Two-way ANOVA: (C) Main effect of Nlgn2 KO, 
F3,207 = 50.63, p<0.0001; Main effect of IgSF9b KO, F3,207 = 25.29, p<0.0001; Interaction between 
genotypes,  
F3,207 = 27.15, p<0.0001. Post hoc paired ttests: *** p< 0.01, compared to WT, ### p< 0.01, compared to 
double KO. n = 6 for WT and IgSF9b KO, n = 4 for Nlgn2 KO and n = 3 for double KO. 
D. Linear correlation coefficient of the normalized CeM high gamma power during all center transitions 
with total time of each mouse in the center of the OF. p = 0.0007, n = 18. 
 
 
to 15% of the increase in Nlgn2 KO (Figure 3.2.9C). This demonstrates that Nlgn2 deletion 
increases gamma band activity in CeM during anxiogenic exploration of the center and that IgSF9b 
deletion in Nlgn2 KOs almost completely rescues this increase.  
 
Finally, we tested whether the increase in normalized power in high gamma range correlates with 
anxiety- like phenotype in the OFT. To this end, we plotted normalized power as a function of 
time spent in the center of the OF by all mice in the study. The less time a mouse spends in the 
center, the higher is the change in high gamma band in the center, with a significant negative 
correlation (Figure 3.2.9D), thus linking high gamma band activity of CeM to behavioral 
manifestation of anxiety.  
 
Taken together, our findings confirm the rescue of anxiety related activation of CeM in double KO   
and demonstrate that IgSF9b deletion normalizes the anxiety- related behavior of Nlgn2 KOs in 
OFT by suppressing the increase in gamma band activity of CeM.  As increase in power of LFP 
indicates increase in synaptic input (Buzsáki et al. 2012), increase  in LFP power in Nlgn2 KOs is 
consistent with their increased anxiety-associated excitatory input to the CeM and enhanced cFOS 
expression in CeM. 
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3.2.7 Summary and Conclusions - Part 1 
 
The goal of the present study was to elucidate the circuit mechanism by which deletion of novel 
synaptic adhesion protein IgSF9b rescues the anxiety related phenotype of Nlgn2 KOs. To this 
end, I show that IgSF9b KO modulates the enhancing effect of Nlgn2 KO on anxiety-associated 
activation of basal and centromedial amygdala. Specifically, IgSF9b KO elevates cFOS expression 
in basal amygdala and reduces cFOS expression in centromedial amygdala in Nlgn2 KOs.  
Dissecting the cFOS expression pattern in basal amygdala to neural components revealed that 
although IgSF9b KO upregulates anxiety-associated activation of the inhibitory Parvalbumin 
network, it does not suppress the excitatory output of basal amygdala to centromedial amygdala in 
Nlgn2 KOs, indicating that the rescue of anxiety related phenotype is predominantly mediated by 
local mechanism in centromedial amygdala. To further investigate this rescue in vivo, we 
performed recordings of local field potentials of centromedial amygdala in mice under anxiogenic 
conditions. Analysis of these recordings showed that IgSF9b KO decreases the activity of 
centromedial amygdala in gamma frequency range (70-120 Hz) in Nlgn2 KOs, and that the 
magnitude of gamma band activity in centromedial amygdala directly correlates with the extent of 
anxiety related phenotype.  
 
Taken together, these findings demonstrate that IgSF9b KO rescues the anxiety related phenotype 
of Nlgn2 KO by modulating anxiety associated neural activity in centromedial amygdala in vivo. 
Following experiments aimed to characterize the cellular and molecular mechanism of this 
modulation. 
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Part 2- Molecular Characterization of Nlgn2 KO and IgSF9b KO in Basal and Centromedial 
amygdala.  
 
3.2.8 IgSF9b is Widely Expressed in the Brain 
  
To begin to address the cellular mechanisms underlying the rescue of anxiety- associated activation 
in CeM in double KOs, I first examined the expression pattern of IgSF9b in the brain of adult 
mouse. IgSF9b is expressed in many brain regions, including cortex, striatum, amygdala and 
cerebellum and, to a lesser extent in hippocampus (Figure 3.2.10), similarly to its expression 
pattern in rat brain (Woo et al. 2013).  
 
 
 
Figure 3.2.10| IgSF9b expression in the brain. 
Low magnification photomicrographs of coronal sections show IgSF9b expression in WT mouse (upper 
panel) and non- specific binding of IgSF9b antibody in IgSF9b KO (lower panel). Anterio- posterior 
coordinates from Bregma are indicated in the uppermost panel.  
 
 
3.2.9 IgSF9b Does Not Colocalize with Synaptic Markers In Vivo 
 
Next, I characterized the synaptic expression of IgSF9b in BA. For this purpose, I performed 
double labeling of IgSF9b with synaptic markers gephyrin, Nlgn2, PSD- 95 and VGAT. IgSF9b  
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Figure 3.2.11| IgSF9b expression and colocalization with synaptic markers in basal amygdala.  
A. Photomicrographs showing IgSF9b expression in basal amygdala (upper panel), IgSF9b localization at 
cell membrane (middle panel) and IgSF9b puncta (lower panel). 
B-E. Photomicrographs showing low degree of colocalization with post synaptic markers gephyrin (B), 
Nlgn2 (C), PSD- 95(D) and presynaptic marker VGAT (E). Scale bars, 100 m (upper), 2 m (middle) and 
1 m (lower).  
 
 
is highly expressed in basal amygdala; its punctate appearance and delineation of the cell body 
suggests that IgSF9b is a synaptic protein (Figure 3.2.11A). IgSF9b is apposed but does not fully 
overlap with any of the synaptic markers analyzed, although partial overlapping with gephyrin and 
Nlgn2 may be observed (Figure 3.2.11B-E). This result resembles the expression pattern of IgSF9b 
in cultured neurons, where clusters of IgSF9b were shown to be closely apposed but not to fully 
overlap with gephyrin clusters (Woo et al. 2013), supporting the notion that IgSF9b is localized in 
the periphery of inhibitory synapses and not at the core of inhibitory postsynaptic sites that contain 
gephyrin and GABA receptors.   
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Figure 3.2.12| Colocalization of IgSF9b with 2 subunit of GABA receptor in centromedial amygdala 
compared to colocalization of Nlgn2 with inhibitory markers. 
Photomicrograph of Nlgn2 and gephyrin puncta (left) shows a high degree of colocalization of two directly 
interacting proteins. Nlgn2 and VGAT (middle) puncta do not colocalize but opposed to each other, 
similarly to IgSF9b and GABAr2 puncta in CeM (right). Scale bar, 1 m. 
 
 
3.2.10 IgSF9b is Apposed to Gamma 2 Subunit of GABA Receptor in Centromedial 
Amygdala 
 
IgSF9b was shown to be tightly associated with Gamma 2 subunit of GABA receptor (GABAr2 
subunit) at the postsynaptic sites (Woo et al. 2013). Therefore, I investigated the degree of the 
colocalization between IgSF9b and GABAr2 subunit in CeM. I compared double-labelled IgSF9b 
and GABAr2 puncta to highly colocalized Nlgn2 and gephyrin puncta and to closely apposed 
Nlgn2 and VGAT puncta. IgSF9b-GABAr2 and Nlgn2-VGAT have similar colocalization 
patterns (Figure 3.2.12), suggesting that unlike gephyrin and Nlgn2, IgSF9b does not directly 
interact with GABA receptors and is localized in close apposition to inhibitory synapses in CeM.  
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Figure 3.2.13| Amygdala expression of inhibitory post synaptic partners of Nlgn2 and IgSF9b. 
A. Schematic representation of known postsynaptic interactions of Nlgn2 and IgSF9b at inhibitory 
synapses. 
B-F. Photomicrographs of expression of IgSF9B (B), gephyrin (C), S-SCAM (D), 1 subunit of GABA 
receptor (E) and 2 subunit of GABA receptor (F) in amygdala. Scale bar, 200 m. 
 
 
3.2.11 IgSF9b and Its Post Synaptic Partners are Expressed in Basal and Centromedial 
Amygdala 
 
The only established post synaptic partners of IgSF9b are S-SCAM, a scaffold protein that was 
shown to be expressed at the majority of inhibitory synapses in cell cultures.  S-SCAM binds 
Nlgn2, that in turn binds gephyrin and GABA receptors, and hence bridges IgSF9b and GABA  
receptors (Figure 3.2.13A) and potentially mediates the effect of IgSF9b deletion on inhibitory 
synaptic transmission (Woo et al. 2013; Sumita et al. 2007; Poulopoulos et al. 2009).  To test this  
hypothesis, I first showed that IgSF9b, S-SCAM, Nlgn2, gephyrin and two subunits of GABA 
receptors, andsubunit, are expressed in BA and CeM (Figure 3.2.13B- F). 
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Figure 3.2.14| Effect of Nlgn2 and IgSF9b deletion on composition of perisomatic GABA receptors in 
basal and centromedial amygdala.  
A-B. Photomicrographs showing perisomatic GABAr1 puncta in basal (A) and centromedial (B) 
amygdala. Scale bar, 2 m. 
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C-F. Density (C, E) and size (D, F) of GABAr1 puncta in WT, Nlgn2 KO, IgSF9b KO and double KOs 
in basal (C, D) and centromedial (E, F) amygdala.  Two-way ANOVA: (C) Main effect of Nlgn2 KO, F3,21 
= 13.25, p = 0.0015, no significant main effect of IgSF9b KO. (D) Main effect of Nlgn2 KO, F3,21 = 13.69, 
p = 0.0013; no significant main effect of IgSF9b KO. (E) Main effect of Nlgn2 KO, F3,24 = 7.73, p = 0.0112, 
main effect of IgSF9b KO, F3,24 = 6.38, p = 0.0196. (F) No significant main effect of Nlgn2 KO, main effect 
of IgSF9b KO, F3,24 = 8.15, p = 0.0095.   No significant interaction between genotypes. Post hoc paired 
ttests: * p C 0.05, ** p< 0.01, *** p< 0.001 compared to WT; # p < 0.05, ## p< 0.01, compared to double 
KO. n = 5-7 (C, D), n= 6-7 (E, F) for each genotype. 
G-J. Density (G, I) and size (H, J) of GABAr2 puncta in WT, Nlgn2 KO, IgSF9b KO and double KOs in 
basal (G, H) and centromedial (I, J) amygdala. No significant main effect of the genotype.  No significant 
interaction between genotypes.  n = 7-8. All bars represent mean + SEM. 
 
 
3.2.12 Nlgn2 KO and IgSF9b KO Reduce Perisomatic GABArPuncta in Brain Region- 
Specific Manner 
 
Next, I investigated whether deletion of Nlgn2 and IgSF9b alters the number and/or composition 
of GABA receptors in BA and CeM. I quantified the number and size of GABArand 
GABArpuncta in Nlgn2 KOs, IgSF9b KOs, double KOs and WTs. I limited my initial analysis  
to perisomatic sites, as I showed previously that Nlgn2 deletion alters inhibitory synaptic 
composition specifically at perisomatic sites. In BA, deletion of Nlgn2 robustly reduces the 
number and size of perisomatic GABArpuncta in Nlgn2 KO and double KO (Figure 3.2.14A, 
C-D). This finding establishes a molecular mechanism for previously shown reduced inhibitory 
transmission in BA of Nlgn2 KOs. IgSF9b deletion does not alter GABArpuncta, suggesting 
that IgSF9b does not regulate GABA receptors in BA at all, or acts at small population of BA 
neurons that was not assessed in the analysis. 
 
Strikingly, in CeM, IgSF9b deletion reduces the number and size of perisomatic GABArpuncta 
in IgSF9b KO and in double KO (Figure 3.2.14B, E-F). This finding suggests that IgSF9b regulates 
inhibitory synaptic composition, and that it does so in brain region- specific manner. Nlgn2 KO 
reduces the number, but unlike in BA, not the size of GABArpuncta (Figure 3.2.14B, E-F),  
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Figure 3.2.15| Effect of Nlgn2 and IgSF9b deletion on perisomatic expression of gephyrin in basal 
amygdala. 
A. Photomicrographs of perisomatic gephyrin expression in WT, Nlgn2 KO, IgSF9b KO and double KOs. 
Scale bar, 2 m. 
B-C. Density (B) and size (C) of gephyrin puncta in basal amygdala.  Two-way ANOVA: (B) Main effect 
of Nlgn2 KO, F3,27 = 6.48, p = 0.0184, no significant main effect of IgSF9b KO. (C) Main effect of Nlgn2 
KO, F3,27 = 7.19, p = 0.013; no significant main effect of IgSF9b KO.  No significant interaction between 
genotypes. Post hoc paired ttests: * p C 0.05, ** p< 0.01, compared to WT; # p < 0.05 compared to double 
KO. n = 7 for each genotype. All bars represent mean + SEM. 
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suggesting that similarly to IgSF9b, function of Nlgn2 at the synapses may vary in distinct brain 
regions.  
 
Finally, neither Nlgn2 KO nor IgSF9b KO alter the expression of GABArpuncta in BA and 
CeM (Figure 3.2.14G-J). As GABAr is thought to be a constitutive subunit of GABA receptors 
(Günther et al. 1995), this finding suggests that Nlgn2 and IgSF9b stabilize receptors containing 
specific GABA receptor subunits (e.g. subunit, rather than overall GABA receptors, at the 
postsynaptic membrane.  
 
3.2.13 IgSF9b KO Does Not Rescue the Deficit in Gephyrin Puncta in Basal Amygdala of 
Double KOs 
 
Next, I investigated the mechanism that underlies reduction of perisomatic GABArpuncta in 
BA of Nlgn2 KOs and double KOs. Nlgn2 drives clustering of synaptic GABA receptors through  
interaction with scaffold protein gephyrin (Poulopoulos et al. 2009)  and I previously showed that 
Nlgn2 deletion reduces gephyrin puncta at perisomatic sites in BA of Nlgn2 KOs. This points out 
that deficit in GABAr puncta in Nlgn2 KOs is caused by loss of gephyrin. To determine 
whether IgSF9b deletion modulates this mechanism in BA of double KOs, I quantified number 
and size of perisomatic gephyrin puncta in BA of Nlgn2 KOs, IgSF9b KOs and double KOs. Nlgn2  
KO reduces the size and number of gephyrin puncta both in Nlgn2 KOs and double KOs, while 
IgSF9b deletion does not alter gephyrin puncta (Figure 3.2.15A-C). This finding demonstrated that 
loss of gephyrin correlates with the reduction of GABArin BA in Nlgn2 KOs and double KOs 
and supports previous conclusion that IgSF9b does not modulate the composition of inhibitory 
synapses in BA. 
 
3.2.14 Nlgn2 KO and IgSF9b KO Do Not Alter Gephyrin and S-SCAM Puncta in 
Centromedial Amygdala 
 
Finally, I tested whether loss of gephyrin may explain the reduction in perisomatic GABAr1 
puncta in CeM of Nlgn2 KOs, IgSF9b KOs and double KOs.  Analysis of perisomatic gephyrin 
puncta in CeM revealed that IgSF9b deletion and, surprisingly, Nlgn2 deletion does not reduce the  
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Figure 3.2.16| Effect of Nlgn2 and IgSF9b deletion on perisomatic expression of post synaptic 
scaffold proteins in centromedial amygdala. 
A-B. Density (A) and size (B) of gephyrin puncta in centromedial amygdala in WT, Nlgn2 KO, IgSF9b 
KO and double KOs.  No significant main effect of genotype.  No significant interaction between genotypes. 
n =6 for each genotype. 
C-D. Density (C) and size (D) of S-SCAM puncta in centromedial amygdala in WT, Nlgn2 KO, IgSF9b 
KO and double KOs. No significant main effect of genotype.  No significant interaction between genotypes. 
n =5 for each genotype. All bars represent mean + SEM. 
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number and the size of gephyrin puncta in CeM (Figure 3.2.16A-B). This suggests that Nlgn2 
regulates composition of GABA receptors by more than one mechanism, and that this mechanism 
depends on the brain region. 
 
As both Nlgn2 and IgSF9b bind to scaffold protein S-SCAM at inhibitory postsynaptic sites (Woo 
et al. 2013), S-SCAM is another possible candidate to mediate the effect of Nlgn2 deletion and 
IgSF9b deletion on GABAr1 puncta in CeM. To test this, I analyzed perisomatic S-SCAM 
expression in CeM, but found no significant difference in number and size of S-SCAM puncta in  
any of the genotypes (Figure 3.2.16 C-D). Therefore, Nlgn2 and IgSF9b regulate the expression 
of GABAr1 puncta in CeM by a mechanism that does not require loss of gephyrin and S-SCAM 
from a postsynaptic membrane. 
 
3.2.15 Nlgn2 KO and IgSF9b KO Perturb the Composition of Specifically Perisomatic 
Synapses 
 
To determine whether the effect of Nlgn2 KO and/or IgSF9b KO on composition of inhibitory 
synapses is specific to perisomatic sites, I quantified the overall intensity of GABAr1 puncta,  
GABArpuncta and gephyrin puncta in BA, and in addition, S-SCAM puncta in CeM (Figure 
3.2.17A-C). There is no difference in overall expression of any of those proteins across genotypes 
in BA (Figure 3.2.17E-I) and in CeM (Figure 3.2.17G-K), confirming that Nlgn2 and IgSF9b 
regulate synaptic composition exclusively at perisomatic sites. Interestingly, GABAr1 puncta 
appear to be particularly dense in the areas surrounding the cell bodies compared to 
GABArpuncta (Figure 3.2.17 C-D), suggesting that distinct subunits of GABA receptors may 
be differentially enriched in perisomatic domains.  
 
3.2.16 Nlgn2 KO and IgSF9b KO Do Not Alter the Overall Number of Inhibitory and 
Excitatory Synapses in Basal Amygdala 
 
Nlgn2 was shown to regulate synaptic formation in cultures (Graf et al. 2004), but synaptogenic 
activity of Nlgn2 or IgSF9b in BA was never studied. Therefore, I investigated whether Nlgn2 KO 
or IgSF9b KO reduces the number of inhibitory and excitatory synapses at perisomatic sites in BA  
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Figure 3.2.17| Overall expression of post synaptic partners of Nlgn2 and IgSF9b in Nlgn2 KO, IgSF9b 
KO and double KO mice.  
A-D. Photomicrographs of gephyrin (A), S-SCAM (B), GABAr1 (C) and GABAr2 (D) staining from 
which the total intensity of staining was assessed. White arrows indicate cell bodies with dense perisomatic 
GABAr1 staining. Scale bar, 10 m. All bars represent mean + SEM. 
(E-F, I). Total intensity of GABAr1 (E), GABAr2 (F) and gephyrin (I) staining in basal amygdala. No 
significant effect of genotype. No significant interaction between genotypes. n = 5 (E, F), n = 7 (I) for each 
genotype. 
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(G-K). Total intensity of GABAr1 (G), GABAr2 (H), gephyrin (J) and S-SCAM (K) staining in 
centromedial amygdala. No significant effect of genotype. No significant interaction between genotypes. n 
= 6 (G, J), n = 7 (H), n = 5 (K) for each genotype.  
 
 
 
Figure 3.2.18| Total number of perisomatic synapses and VGAT/Vglut2 ratio in basal amygdala of 
Nlgn2 KO, IgSF9b KO and double KOs. 
A. Photomicrograph of VGAT and Vglut2 puncta surrounding the neuron body in basal amygdala. Scale 
bar, 2 m.  
B-D. Density of VGAT puncta (B), Vglut2 puncta (C) and VGAT/Vglut2 ratio (D) in WT, Nlgn2 KO, 
IgSF9b KO and double KOs. No significant effect of genotype. No significant interaction between 
genotypes. n = 7 for each genotype. All bars represent mean + SEM.  
 
 
and/or alters the ratio between inhibitory and excitatory synapses. To that end, I labelled the 
inhibitory synapses with VGAT and the excitatory synapses with Vglut2 (Figure 3.2.18A), 
quantified the number of perisomatic VGAT and Vglut2 puncta and calculated VGAT/Vglut2 
ratio. I observed no change in number of VGAT puncta, Vglut2 puncta and VGAT/Vglut2 ratio 
across the genotypes (Figure 3.2.18B-D). 
 
3.2.17 Nlgn2 KO Impairs Inhibitory Synaptic Transmission in Basal Amygdala 
 
I showed previously that Nlgn2 KO reduces the frequency of mini inhibitory post-synaptic currents 
(mIPSCs) in BA. To investigate whether IgSF9b KO modulates this inhibitory deficit in double 
KO and/or otherwise alters inhibitory transmission in BA, I measured miniature inhibitory  
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Figure 3.2.19| Effect of Nlgn2 KO and IgSF9b KO on inhibitory synaptic transmission in basal 
amygdala.  
A-B. Low magnification photomicrograph showing the location of recordings (A) and sample traces from 
basal amygdala of WT, Nlgn2 KO, IgSF9b and double KO (B). 
C-D. Average frequency (C) and amplitude (D) of mIPSCs in excitatory neurons of basal amygdala. n = 
14 (WT), n = 6 (Nlgn2 KO, IgSF9b KO) and n = 9 (double KO). Unpaired ttest: * p < 0.05 compared to 
WT. All bars represent mean + SEM. 
 
postsynaptic currents (mIPSCs) in the excitatory neurons in BA of Nlgn2 KOs, IgSF9b KOs and 
double KOs. Additional data should be collected to reach a statistical significance, however a 
reduction in mIPSC frequency is readily observed in BA of Nlgn2 KO mice and double KOs, but 
not in IgSF9b KO (Figure 3.2.19B-C). This suggests that IgSF9b KO does not rescue the major 
inhibitory deficit caused by Nlgn2 KO in BA, consistent with lack of effect of IgSF9b KO on 
inhibitory synaptic composition in BA. Nlgn2 KO also significantly reduces the amplitude of 
mIPSCS, but this reduction is less pronounced in double KOs, suggesting that IgSF9b KO may 
modulate this effect in Nlgn2 KO (Figure 3.2.19D). Interestingly, mIPSC kinetics were 
significantly altered in IgSF9b KO (rise time: WT = 488.52 s, IgSF9b KO = 720.34 s, p = < 
0.0001; decay time: WT = 10.31 ms, IgSF9b KO = 13.33 ms, p = 0.0025), indicating that IgSF9b 
may indeed subtly regulate the inhibitory transmission in BA. 
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Figure 3.2.20| Effect of Nlgn2 KO and IgSF9b KO on inhibitory synaptic transmission in 
centromedial amygdala.  
A-B. Low magnification photomicrograph showing the location of recordings (A) and sample traces from 
centromedial amygdala of WT, Nlgn2 KO, IgSF9b and double KO (B). 
C-D. Average frequency (C) and amplitude (D) of mIPSCs of inhibitory neurons in centromedial amygdala. 
Two-way ANOVA: (C) Main effect of Nlgn2 KO, F3,59 = 1.24, p = 0.271, main effect of IgSF9b KO, F3,59 
= 5.45, p = 0.023. No significant interaction between genotypes. Post hoc paired ttests: *p<0.05,  
 compared to WT. n = 16 (WT), n = 13 (Nlgn2 KO), n = 12 (IgSF9b KO) and n = 14 (double KO). All bars 
represent mean + SEM 
E. Cumulative probability plot of mIPSCs frequencies. Kolmogorov- Smirnov statistical analysis: IgSF9b 
vs WT, p < 0.0001; double KO vs WT, p < 0.0001; Nlgn2 KO vs Double KO, p < 0.05; Nlgn2 vs WT, not 
significant.  
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3.2.18 IgSF9b KO Enhances Inhibitory Synaptic Transmission in Centromedial Amygdala 
of Nlgn2 KOs 
 
Next, I investigated the effect of Nlgn2 KO and IgSF9b KO on inhibitory synaptic transmission in 
CeM. Mesuring mIPSCS in CeM revealed that IgSF9b KO increases the frequency of mIPSCS 
compared to WT, while Nlgn2 KO does not affect the frequency and amplitude of mIPSCS (Figure 
3.2.20B-C). While in double KO the mean frequency of mIPSCs is not significantly different from 
WT, analyzing the frequency values distribution revealed a significant shift towards higher values  
in IgSF9b KO and double KO (Figure 3.2.20E).  No significant change in kinetics of mIPSCs was 
observed across genotypes. Interestingly, the kinetics were slower compared to BA (rise time: 
BA= 488.52 s, CeM=978s; decay time: BA=10.31 ms, CeM=15.1 ms for WT). Combined with 
results obtained from BA, these findings demonstrate that IgSF9b modulates inhibitory 
transmission predominantly in CeM and not in BA. Moreover, IgSF9b KO enhances the inhibitory 
transmission in CeM of Nlgn2 KOs, indicating that IgSF9b and Nlgn2 may interact in CeM in a 
way that leads to reversal of CeM overactivation in double KOs. 
 
3.2.19 IgSF9b may be a novel regulator of inhibitory synapses onto inhibitory neurons 
  
What cellular mechanism may underlie the striking CeM- specificity of IgSF9b function? To begin 
to address this question, I compared the neuronal composition of BA vs CeM by taking advantage 
of transgenic mice in which neurons expressing inhibitory marker VGAT are labelled with GFP. 
BA is a cortical-like structure and as expected, only a small population of BA neurons (~ 20%) is 
inhibitory. In stark contrast, the majority of CeM neurons are inhibitory (Figure 3.2.21A), 
indicating that almost all the inhibitory post synaptic sites in CeM belong to inhibitory neurons. 
Therefore, the specificity of IgSF9b function may be explained in terms of specificity towards 
inhibitory synapses onto inhibitory neurons, positioning IgSF9b as potentially the first known 
synaptic organizer of specific subpopulation of inhibitory synapses.  
 
Finally, I investigated whether the neuron population in CeM is homogeneous by labelling CeM 
with inhibitory markers PV, SOM, calretinin and calbindin. PV, SOM and calretinin were all 
expressed at very low levels in CeM (images not shown) and calbindin labeled ~ 60% of neurons  
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Figure 3.2.21| Expression of VGAT and Calbindin in centromedial nucleus. 
A. Photomicrograph showing GFP expression in basal and centromedial amygdala of mouse in which 
VGAT expressing neurons are tagged with GFP (Venus- Vgat mouse). Scale bar, 200 m. 
B. Colocalization of GFP and inhibitory marker Calbindin in centromedial nucleus of Venus- Vgat mouse. 
Scale bar, 50 M.  
 
 
in CeM (Figure 3.2.21B). This suggests that there are at least two populations of inhibitory neurons 
in CeM that differentially express calbindin. Future studies will show whether IgSF9b functional 
specificity depends not only on the type of the synapse but also on the type of inhibitory neuron.   
 
3.2.20 Summary and Conclusions - Part 2 
 
The goal of the present study was to describe the cellular and molecular mechanism by which 
IgSF9b KO rescues the activity enhancement of CeM during anxiety processing in Nlgn2 KOs. To 
this end, I characterized the expression pattern of IgSF9b in the brain and showed that IgSF9b is 
expressed in most brain regions and is localized at subsynaptic domain at the periphery of 
inhibitory synapses. Next, I focused on four possible common synaptic partners of both IgSF9b 
and Nlgn2, and tested whether their expression levels in BA and CeM are altered by Nlgn2 KO 
and/or IgSF9b KO. In addition, I quantified the number of inhibitory and excitatory synapses in 
basal amygdala. The results of molecular characterization of Nlgn2 and IgSF9b KO mice are 
summarized in Table 3.2.1. 
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Table 3.2.1| Effect of Nlgn2 KO and IgSF9b KO on molecular composition of inhibitory synapses in 
basal and central amygdala. 
 
 Nlgn2 KO IgSF9b KO 
 BA   CeM  BA  CeM 
     
 Perisomatic Overall Perisomatic Overall Perisomatic Overall Perisomatic Overall 
         
GABAr1  ↔  ↔ ↔ ↔  ↔ 
GABAr2 ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
Gephyrin  ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
S-SCAM NA NA ↔ ↔ NA NA ↔ ↔ 
VGAT ↔ ↔ NA NA ↔ ↔ NA NA 
Vglut2 ↔ ↔ NA NA ↔ ↔ NA NA 
 
    - reduction in number and size of the puncta 
- reduction in number of the puncta 
NA     -  not available  
 
All the molecular alterations showed in the table above are present in the double KO, suggesting 
that IgSF9b KO and Nlgn2 KO do not reciprocally modulate each other’s effect on composition 
of inhibitory synapses in BA and CeM. Regardless the lack of molecular interaction, IgSF9b KO 
alters synaptic inhibitory transmission in CeM of Nlgn2 KO, suggesting that Nlgn2 and IgSF9b 
may interact on cellular level specifically at CeM. 
 
Together, these findings demonstrate that IgSF9b KO may decrease anxiety-associated activation 
of CeM in Nlgn2 KO by restoring the inhibitory transmission onto the CeM neurons through 
currently unknown synaptic interaction. As most of the inhibitory synapses in CeM contact 
inhibitory neurons, my findings raise an intriguing possibility that inhibitory synapses onto 
inhibitory neurons may be critical for regulation of anxiety processing, thus offering a novel target 
for pharmacotherapy of anxiety disorders.
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4. DISCUSSION 
Using a combination of behavioral assessment, quantitative morphological analysis, cFOS 
induction assay, anatomical tracing and in vivo and in vitro electrophysiology, I show here that 1) 
Nlgn2 deletion in mice produces deficits in the structure and function of perisomatic inhibitory 
synapses in the basal amygdala, accompanied by a prominent anxiety phenotype and a 
corresponding anxiety-associated overactivation of neurons projecting to centromedial amygdala; 
and 2) deletion of IgSF9b alters the structure and enhances the function of inhibitory synapses in 
centromedial amygdala, as well as rescuing the anxiety phenotype and the associated 
overactivation of centromedial amygdala in Nlgn2 KO mice. This is the first comprehensive study 
of the molecular, cellular and circuitry role of cell adhesion proteins in regulating anxiety 
behaviors, as well as the first report of neural correlates of anxiety processing in vivo in 
centromedial amygdala. My findings indicate that Nlgn2 and IgSF9b bidirectionally regulate 
anxiety-related behaviors by modulating inhibitory transmission in distinct parts of the anxiety- 
processing circuit. Thus, my work provides important insights both into the molecular mechanisms 
by which mutations in Nlgn2 and IgSF9b may contribute to psychiatrically relevant phenotypes 
and into the functional role of amygdala in anxiety processing. 
 
4.1 Consequences of Nlgn2 and IgSF9b Deletion on Anxiety- Related Behavior in Mice 
 
4.1.1 Consequences of Nlgn2 Deletion on Anxiety- Related Behavior 
 
As reported previously (Blundell et al. 2009), deletion of Nlgn2 leads to robust anxiety phenotype 
that I confirmed in a battery of three well validated anxiety assays: elevated plus- maze (EPM), 
open field test (OFT) and light- dark box (LD). These tests exploit the natural aversion of mice 
towards elevated, exposed and brightly lit areas (Rodgers & Dalvi 1997; Carola et al. 2002) and 
are the tests of choice for evaluating unconditioned anxiety-related behaviors.  
 
Since EPM, OFT and LD require novelty-induced exploration of neutral and aversive 
compartments of the test chambers, non- anxiety related alterations in locomotor activity of the 
mice may confound their anxiety phenotype. Although I found that Nlgn2 KO mice showed 
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reduced locomotor activity during anxiety testing as previously reported (Wöhr et al. 2014), 
correction of activity in anxiogenic compartments for overall activity levels did not reduce the 
robustness of anxiety phenotype of Nlgn2 KO mice (Figure 3.1.1). Moreover, I confirmed that the 
reduced locomotor activity of Nlgn2 KO mice during anxiety assessment is due to novelty- 
induced enhancement of freezing behavior and not due to a primary locomotor impairment. 
Therefore, the reported reduction of exploratory activity in Nlgn2 KO mice, which was measured 
under anxiogenic conditions in the OFT (Wöhr et al. 2014), reflects their anxiety phenotype. Nlgn2 
KO mice demonstrated strong thigmotaxis during OFT which prompted me to include peripheral 
areas of the open field chamber, in addition to the customary center zone, in the behavioral analysis 
(Figure 3.2.2). Taken together, these findings demonstrate that Nlgn2 regulates anxiety- related 
behavior in mice. 
 
4.1.2 Consequences of Deletion of IgSF9b in Nlgn2 KO mice on Anxiety- Related Behavior 
 
A decrease in anxiety- related behavior of IgSF9b KO mice was evident in the robust increase in 
the number of entries and the time spent in the center of the OF. However, while there was a 
significant increase in novelty- induced exploration in IgSF9b KO mice, the normalized activity 
in the center of the OF is not significantly different between IgSF9b KO and WT mice, although 
a trend towards decrease in IgSF9b KO mice could be observed (Figure 3.2.1-3.2.2).  Taken 
together, these findings indicate that deletion of IgSF9b mildly reduces the anxiety- related 
phenotype. Characterization of the home cage locomotor activity of IgSF9b KO mice will be 
required to distinguish between a genuine decrease in anxiety behavior and a general increase in 
locomotor activity. 
 
This is the first report of an anxiety- related phenotype of IgSF9b KO mice, which is strikingly 
opposite to the phenotype of Nlgn2 KO mice with respect to both anxiety behavior and locomotion 
during OFT. This indicates that Nlgn2 and IgSF9b may bidirectionally regulate anxiety- related 
behavior. Complete rescue of the anxiety related phenotype in double Nlgn2 x IgSF9b KO mice 
further validates the important role these proteins may have in regulation of anxiety, thus inspiring 
a detailed characterization of individual and collective functions of Nlgn2 and IgSF9b in the 
anxiety- processing circuit.    
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4.2 Consequences of Nlgn2 Deletion on Synaptic Structure and Synaptic Function in the 
Anxiety- Processing Circuit 
 
4.2.1 Effect of Nlgn2 Deletion on Inhibitory Synapses in Basal Amygdala 
 
Consistent with previous reports on dissociated neuronal cultures and retina (Varoqueaux et al. 
2004; Hoon et al. 2009; Poulopoulos et al. 2009)  I show that Nlgn2 is expressed almost exclusively 
at inhibitory synapses in basal amygdala (BA) of adult mice. In line with findings in hippocampus 
of Nlgn2 KO mice, loss of Nlgn2 leads to reduction in gephyrin in BA (Figure 3.2.15). Moreover, 
to my knowledge, this is the first report showing that deletion of Nlgn2 leads to a robust loss of 
the 1 subunit of GABAA receptor (GABAr 1) in the brain (Figure 3.2.14), thus expanding the 
repertoire of Nlgn2 postsynaptic core interactions that so far included gephyrin, collybistin and 
subunit of GABA receptors (Jedlicka et al. 2011; Poulopoulos et al. 2009).  
 
Loss of the GABAr1 subunit was shown to reduce clustering of GABA receptors and impair 
inhibitory transmission in cerebellum, thalamus, lateral amygdala and hippocampus (Sur et al. 
2001; Kralic et al. 2002; Goldstein et al. 2002; Wiltgen et al. 2009). Moreover, a 50% decrease in 
mIPSC frequency and a 20% decrease in mIPSC amplitude was reported in hippocampal 
pyramidal neurons of GABAr1 KO mice (Goldstein et al. 2002), consistent with the substantial 
reduction in mIPSC frequency and a small reduction in mIPSC amplitude in excitatory neurons in 
BA of Nlgn2 KO mice (Figure 3.2.19). The deficit in inhibitory synaptic transmission in Nlgn2 
KO mice may therefore be a direct consequence of loss of the GABAr1 subunit in BA (Figure 
3.2.14).     
 
What is the molecular mechanism underlying the GABAr1 subunit reduction in BA of Nlgn2 
KO mice? The most straightforward explanation is that absence of Nlgn2 reduces the localization 
of gephyrin at the synaptic plasma membrane, thus preventing gephyrin- mediated clustering of 
GABA receptors at the postsynaptic sites. In line with this notion, I observed a marked reduction 
in gephyrin puncta in BA of Nlgn2 KO mice (Figure 3.2.15). However, Nlgn2 was shown to cluster 
GABA receptors in the absence of gephyrin (Kneussel, Helmut Brandstätter, et al. 2001; Fritschy 
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et al. 2006; Dong et al. 2007). Moreover, findings in GABArsubunit KO mice show a dramatic 
loss of gephyrin but preservation of majority of fully functional 1-containing receptors, 
indicating that incorporation of GABAr1 subunit into GABA receptors does not require gephyrin 
(Fritschy et al. 2006). Therefore, the reduction in postsynaptic GABAr1 subunits may point out 
to a novel role of Nlgn2 in direct clustering of 1 subunit- containing GABA receptors in 
amygdala. While in the absence of direct evidence of interaction between Nlgn2 and GABAr1 
subunit this explanation remains speculative, the possible gephyrin- independent interaction 
between Nlgn2 and the 1 subunit may underlie the reduction of 1 receptors in centromedial 
amygdala (see below).  
 
In contrast to previously reported findings in stratum pyramidale of Nlgn2 KO mice (Poulopoulos 
et al. 2009), I did not detect a reduction in number and size of GABArsubunit clusters in the 
BA of Nlgn2 KO mice (Figure 3.2.14). The GABArsubunit was postulated to be a constitutive 
subunit of GABA receptors and to translocate to the neuronal membrane exclusively upon 
clustering with GABAr subunits (Essrich et al. 1998; Kneussel et al. 1999). Unaltered levels of 
the subunit would therefore indicate that deletion of Nlgn2 does not lead to loss of overall 
GABA receptors in BA and instead alters the composition of GABA receptors e.g. by 
compensation with GABAr2 or 3 subunits. By this logic, the resulting receptors must be less 
efficient than original 1 containing receptors to explain the reduction in inhibitory transmission 
in BA. An alternative interpretation arises from a study showing that in mice lacking the 
GABArsubunit, inhibitory transmission is partially preserved and is mediated by GABA 
receptors containing subunit, disproving the essential role of subunit in GABAergic 
transmission (Kerti-Szigeti et al. 2014). Based on this finding, it is conceivable that there is a 
putative subpopulation of GABA receptors in BA which contains 1 and 3 subunits and whose 
clustering is selectively impaired by Nlgn2 deletion, explaining the unaltered level of GABAr2 
subunit in Nlgn2 KO mice. Lending support to this theory, an immunoreactivity for GABAr3 
subunit was detected in basal amygdala (Herb et al. 1992). Further analysis of expression of 
GABAr3 subunit and subunits that were previously shown to compensate for loss of GABAr1 
in amygdala, such as 2 and 3 (Kralic et al. 2002), will clarify whether reduction in 1 subunit 
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reflects reduction in number of GABA receptors or subunit composition change. Regardless of the 
exact mechanism, deletion of Nlgn2 impairs GABAergic transmission in BA. 
 
Interestingly, Nlgn2 deletion in the BA leads to a specific loss of perisomatic inhibitory 
postsynaptic components. In addition to already reported perisomatic reduction in gephyrin 
(Jedlicka et al. 2011; Poulopoulos et al. 2009), I show that loss of Nlgn2 reduces GABAr1 puncta 
strictly at perisomatic synapses (Figure 3.2.17). These findings are particularly interesting in light 
of my observation that almost all gephyrin-positive structures in BA contain Nlgn2, indicating that 
the loss of Nlgn2 at non-perisomatic synapses is compensated by other synaptic adhesion 
molecules such as -dystroglycan and Neurofascin  (Craig & Kang 2007; Panzanelli et al. 2011; 
Burkarth et al. 2007). 
 
What is the possible mechanisms underlying perisomatic reduction of gephyrin in Nlgn2 KO mice? 
It was previously shown that Nlgn2 is required to target gephyrin to the postsynaptic membrane, 
as gephyrin forms large cytoplasmic aggregates in absence of binding to Nlgn2 (Poulopoulos et 
al. 2009). I did not observe an increase in intracellular gephyrin clusters in BA of Nlgn2 KO mice. 
However, I empirically observed stronger gephyrin labelling of axon initial segments (AIS) in 
Nlgn2 KO mice compared to WT mice (Figure 4.1). While this finding awaits quantitative 
verification, it may indicate an intriguing possibility that in absence of Nlgn2, gephyrin is 
preferentially targeted to synapses at AIS on the expense of the somatic synapses, and that gephyrin 
recruitment to perisomatic and AIS synapses requires distinct mechanisms. In line with this 
hypothesis, gephyrin clustering at AIS synapses is dependent on interaction with the adhesion 
protein Neurofascin (Burkarth et al. 2007; Ogawa & Rasband 2008). Therefore, Nlgn2 and 
Neurofascin may be required for perisomatic and AIS targeting of gephyrin, respectively. 
Interestingly, GABAergic synapses at the AIS of BA projection neurons were recently implicated 
in regulation of fear- related behavior (Saha et al. 2017). This indicates that the molecular 
mechanisms balancing the inhibitory input across distinct neuronal compartments, such as 
described above, may be involved in regulating clinically- relevant behaviors. 
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Figure 4.1| Colocalization of Gephyrin and AIS marker Ankyrin G in Nlgn2 KO and WT mice. 
Thick arrows indicate AIS that are not colocalized with gephyrin strings in WT (upper panel). In Nlgn2 
KO, all AIS colocalize with Ankyrin G strings (lower panel). Scale bar, 20 m. 
 
 
The overall number of inhibitory presynapses remains unaffected by Nlgn2 deletion (Figures 3.1.9, 
3.2.18).  This finding is in agreement with multiple reports demonstrating that deletion of 
inhibitory postsynaptic core components including Nlgn2, GABA receptor subunits and gephyrin 
does not affect the expression of presynaptic markers such as GAD 67 and VGAT (Fritschy et al.  
2006; Kneussel et al. 1999; Poulopoulos et al. 2009). One exception to this statement is a study 
that demonstrated a reduction in VGAT in Nlgn2 KO mice, however electron microscopy imaging 
in the same study revealed that the overall number of inhibitory synapses remained unaltered 
(Blundell et al. 2009). Therefore, it may be concluded that Nlgn2 deletion does not alter the number 
of inhibitory contacts in vivo.  
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The strictly perisomatic effect of Nlgn2 deletion is consistent with the observation that loss of 
Nlgn2 in the cerebral cortex specifically affects synaptic connections made by axons of PV-
positive interneurons (Gibson et al., 2009), the primary source of perisomatic inhibition in many 
brain regions, including BA (Muller et al., 2006; Wolff et al., 2014). Interestingly, I observed a 
slight increase in the total number of PV-positive interneurons but no change in the number of 
presynaptic PV-positive terminals, indicating that pruning of the excess inputs may occur during 
early postnatal development (Figure 3.1.9, 3.1.11). Additionally, Cholecystokinin (CCK) 
expressing interneurons were shown to form perisomatic synapses onto excitatory neurons in BA 
(Mascagni & McDonald 2003).  Interestingly, although both GABAr and 2 subunits are 
strongly expressed in BA, post synaptic sites targeted by CCK-positive interneurons in BA contain 
predominantly GABAr subunit (Marowsky et al. 2004). Loss of 1 clusters in Nlgn2 KO mice 
may therefore reflect the effect of Nlgn2 deletion on CCK- positive terminals onto excitatory 
neurons in BA, in addition to a well-documented effect of Nlgn2 deletion on PV- positive 
terminals.  
 
In agreement with a key role for Nlgn2 at perisomatic inhibitory synapses in BA, I observed that 
Nlgn2 deletion results in a pronounced reduction in the frequency and a slight, but significant, 
reduction in the amplitude of mIPSCs of excitatory neurons in BA (Figure 3.2.19). The observed 
reduction in the amplitude is contradictory to the findings of our collaborators Paolo Botta and 
Andreas Luthi (Friedrich Miescher Insitute of Biomedical Research in Basel, Switzerland) and 
may arise from variability in experimental conditions (Figure 3.1.10). Since a reduction in the 
mIPSC amplitude reflects a decrease in the number of GABA receptors and a reduction in the 
mIPSC frequency may reflect decrease in the number of functional postsynaptic sites (Otis et al. 
1994; De Koninck & Mody 1994), my findings are consistent with the molecular alterations of 
inhibitory synapses in Nlgn2 KO mice described above. Alternatively, the reduction in mIPSC 
frequency may point to a change in presynaptic release probability. While the unaltered expression 
of pre-synaptic markers argues against this scenario (Figure 3.2.18), a functional impairment of 
the vesicle release machinery in Nlgn2 KO mice currently cannot be ruled out and will be 
addressed in future experiments.  
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Taken together, my findings indicate that Nlgn2 deletion affects the postsynaptic structure and 
transmission of inhibitory perisomatic synapses onto excitatory neurons in BA. The mechanism 
by which deletion of Nlgn2 would affect only perisomatic synapses is currently unknown, but may 
potentially be explained by the existence of a molecularly heterogeneous synapse population, in 
which Nlgn2 is either redundant or not present in some synapses. Further studies will be required 
to identify the exact molecular mechanisms underlying the function of Nlgn2 in regulating the 
number and/or composition of GABA receptors. As insufficient GABAergic inhibition in BA is 
one of the key mechanisms underlying anxiety- related disorders (Sanders & Shekhar 1995; 
Gauthier & Nuss 2015), my findings place Nlgn2 as a regulator of anxiety- related processing.    
 
4.2.2 Effect of Nlgn2 Deletion on Inhibitory Synapses in Centromedial Amygdala 
 
In stark contrast to its robust effect on inhibitory synapses in BA, the only consequence of Nlgn2 
deletion in centromedial amygdala (CeM) is the reduction in number of perisomatic GABArl 
clusters. The size of alpha1 clusters, the expression of gephyrin, and inhibitory synaptic 
transmission are unaltered in Nlgn2 KO mice (Figure 3.2.14, 3.2.16). The fact that Nlgn2 deletion 
can have brain region- specific effects on mIPSCs was illustrated by previous studies, revealing a 
pronounced decrease in mIPSC frequency and a lesser decrease in amplitude in area CA1 of 
hippocampus (Poulopoulos et al., 2009), but a decrease in mIPSC amplitude without 
accompanying changes in frequency in somatosensory cortex (Gibson et al., 2009) and dentate 
gyrus (Jedlicka et al., 2011). However, a complete lack of effect of Nlgn2 deletion on both mIPSC 
frequency and amplitude has never been reported so far. Even more surprisingly, my finding 
indicates that the well- established role of Nlgn2 in synaptic targeting of gephyrin is not universal 
across the brain, further highlighting the functional heterogeneity of Nlgn2. 
 
Unlike in BA, inhibitory transmission in CeM is mediated predominantly by 2 subunit containing 
GABA receptors (Ortinski et al. 2004; Marowsky et al. 2004). Interestingly, 2 subunit containing 
receptors were reported  to demonstrate slower kinetics of mIPSCs compared to 1 containing 
GABA receptors (Dixon et al. 2014), and accordingly, I observed slower rise and decay times of 
mIPSCs in CeM compared to BA. Based on this notion, one possible explanation for the lack of 
consequences of Nlgn2 deletion on inhibitory synaptic transmission in CeM is that Nlgn2 may be 
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not involved in clustering of subunit containing GABA receptors.  Several lines of evidence 
may support this hypothesis. I observed that Nlgn2 deletion has no effect on number and size of 
GABAr clusters in BA in a small sample of mice (n =3 for each genotype, mean value for WT, 
2.07; mean value for Nlgn2 KO, 1.74; p = 0.56), despite affecting gephyrin and GABAr1 
clustering in this region. Moreover, clustering of 2 subunit requires gephyrin (Tretter et al. 2008) 
which, as I show here, is not affected by Nlgn2 deletion in CeM (Figure 3.2.16). Finally, 2 subunit 
is highly expressed in lateral part of CeA (Marowsky et al. 2004), while I observed that Nlgn2 is 
almost completely absent from the lateral part of CeA (Figure 3.1.7).  Taken together, this may 
possibly indicate that Nlgn2 is not associated with regulation of clustering of the GABAr2 
subunit, and therefore does not affect the inhibitory transmission in CeM. Quantification of 
GABAr2 subunit in CeM and subunit- specific pharmacological manipulations during patch 
clamp recording will be necessary to further test this hypothesis.  
 
4.3 Consequences of IgSF9b Deletion on Synaptic Structure and Synaptic Function in 
Anxiety- Processing Circuit 
 
4.3.1 Subcellular localization of IgSF9b 
 
Analysis of postsynaptic density components showed tight association of IgSF9b with 
GABArsubunit, indicating that IgSF9b is a synaptic protein (Woo et al. 2013). In dissociated 
hippocampal cultures, IgSF9b was shown to colocalize with VGAT, gephyrin and Nlgn2, but not 
with excitatory markers, further supporting its association with inhibitory synapses. Finally, super-
resolution imaging demonstrated that IgSF9b is localized to a subsynaptic domain at a nanoscale 
distance from core components of inhibitory synapses (Woo et al. 2013). My findings that IgSF9b 
clusters 1) have punctuate appearance typical of synaptic clusters; and 2) are closely apposed to 
2 subunit (Figure 3.2.12), are in line with the notion that IgSF9b is expressed at the periphery of 
inhibitory synapses. A similar subsynaptic organization was previously demonstrated for 
excitatory synapses, where the cell adhesion protein N-cadherin and glutamatergic receptors are 
localized in two distinct synaptic compartments (Uchida et al. 1996). However, it is important to 
mention that I did not systematically analyze the distance between IgSF9b clusters and inhibitory 
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synaptic markers that were closely associated, but did not colocalize with IgSF9b. Therefore, at 
this stage, I cannot rule out the possibility that IgSF9b is an extrasynaptic membrane protein. 
 
4.3.2 Consequences of IgSF9b deletion in basal amygdala 
 
Deletion of IgSF9b did not affect the synaptic composition and only slightly altered synaptic 
transmission at inhibitory synapses onto excitatory neurons in BA. While the frequency and the 
amplitude of mIPSCs were similar between IgSF9b KO and WT mice, there was a significant 
increase in the rise time and the decay of mIPSCs in IgSF9b KO mice (Figure 3.2.19). This increase 
may reflect an alteration in the subunit composition of GABA receptors, specifically in alpha 
subunits which determine the kinetics of the receptor- mediated currents (Vicini et al. 2001).  
 
Mostly unaltered inhibitory transmission onto excitatory neurons in IgSF9b KO mice is consistent 
with the report that knock-down of IgSF9b predominantly affects inhibitory synapses onto 
inhibitory neurons. My findings confirm the observation from cell cultures that IgSF9b lacks the 
ability to cluster gephyrin (Woo et al. 2013), as I observed no deficits in gephyrin expression in 
IgSF9b KO mice (Figure 3.2.15). Taken together, these findings indicate that IgSF9b is not 
majorly involved in regulation of inhibition of excitatory neurons in BA. 
 
4.3.3 Consequences of IgSF9b Deletion in Centromedial Amygdala 
  
In contrast to BA, I found that loss of IgSF9b leads to reduction in number and size of 1 subunit 
and to enhancement of inhibitory synaptic transmission in CeM (Figures 3.2.14, 3.2.20). As I and 
others showed that CeM contains predominantly inhibitory neurons, this finding indicates that 
IgSF9b may be a specific regulator of inhibitory transmission onto inhibitory neurons. While 
knockdown of IgSF9b in cell cultures was shown to reduce the frequency of mIPSCs (Woo et al. 
2013), the discrepancy with my results obtained from adult animals may arise from differential 
makeup of GABAergic receptors during distinct stages of neuronal development (Ortinski et al. 
2004). 
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While the exact mechanism of upregulation of inhibitory transmission in CeM of IgSF9b KOs is 
currently unknown, it may involve compensatory upregulation of GABAr2 and 3 subunits that 
was previously demonstrated in the forebrain, amygdala and cerebellum of subunit KO mice 
(Sur et al. 2001; Kralic et al. 2002; Wiltgen et al. 2009).  It is important to note that during 
electrophysiological characterization of Nlgn2 and IgSF9b KO mice I did not rule out that the 
effect observed mIPSCs frequencies is caused by presynaptic mechanism that affects vesicle 
release. Further experiments to determine vesicle release probability or the size of readily 
releasable pool will address the potential contribution of presynaptic mechanisms to inhibitory 
transmission in Nlgn2 KO and IgSF9b KO mice.  
 
As I did not observe any alterations in size and number of S-SCAM (Figure 3.2.16), a scaffold 
protein that was proposed to bridge IgSF9b with core components of inhibitory synapse (Woo et 
al. 2013), the molecular mechanism underlying loss of 1 in CeM of IgSF9b KO mice is currently 
unknown. Electron microscopy imaging to determine the precise localization of IgSF9b within 
neurons might be required to begin to untangle the interactions of IgSF9b underlying its synaptic 
function. Regardless of the mechanism, deletion of IgSF9b upregulates inhibitory transmission in 
CeM, which may supress the anxiogenic output of CeM during anxiety- related processing. 
 
4.4 Synaptic Structure and Synaptic Function in Anxiety- Processing Circuit in Double 
Nlgn2 IgSF9b KO mice 
 
Most of the outcomes of Nlgn2 and IgSF9b deletion on synaptic composition and function are 
present in double KO mice. Accordingly, double KO mice demonstrate a reduction of perisomatic 
gephyrin and GABAr1 subunit clusters and strong trend for reduction of mIPSCs frequency in 
BA, as well as reduction in number and size of 1 subunit clusters and a shift towards high- 
frequency mIPSCs in CeM (Figures 3.2.14, 3.2.15, 3.2.20). Interestingly, unlike in Nlgn2 KO 
mice, the amplitude of mIPSCs in BA of double KO mice is not significantly different from the 
WT mice. However, it should be highlighted that all the data from in vitro electrophysiological 
experiments in IgSF9b and double KO mice is preliminary and should be further expanded to be 
conclusive.  
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Lack of modulatory effect of IgSF9b deletion on outcomes of  Nlgn2 deletion strongly suggests 
that Nlgn2 and IgSF9b do not interact with each other at the synaptic and cellular level. Therefore, 
the rescue of anxiety- related behavior in double KO mice must occur at the circuit level, by IgSF9b 
deletion- conferred alteration of anxiety-associated activity of the networks within and/or across 
the BA and CeM. 
 
4.5 Consequences of Nlgn2 and IgSF9b Deletion on Excitatory and Inhibitory Networks in 
Basal Amygdala 
 
4.5.1 Consequences of Nlgn2 deletion on Neurons in BA 
 
Despite a near-universal presence of Nlgn2 at inhibitory synapses in BA, only CaMKII-positive 
glutamatergic projection neurons show differential induction of cFOS in Nlgn2 KO mice under 
anxiogenic conditions. These neurons project to a number of target regions known to mediate 
anxiety behaviors, including the CeA, hippocampus, bed nucleus of the stria terminalis, and 
prefrontal cortex  (Felix-Ortiz et al. 2013; Namburi et al. 2015; Lebow & Chen 2016; Sotres-Bayon 
et al. 2012). Specifically, the glutamatergic projection from BA to CeM was recently implicated 
in mediation of anxiety- related behavior during exploration of a novel environment (Namburi et 
al. 2015). In line with this finding, I show that projection neurons in BA that target CeM show 
enhanced anxiety- associated cFOS induction in Nlgn2 KO mice (Figure 3.2.6). 
 
In contrast, the complex inhibitory network of local Parvalbumin  (PV) - and Somatostatin  (SOM) 
-positive interneurons, which play an essential role in regulating neuronal plasticity and learning 
in the BA (Wolff et al. 2014; Ehrlich et al. 2009) shows no differential cFOS expression under 
anxiogenic conditions, even though both types of interneurons receive perisomatic innervation 
from PV-positive terminals (Muller et al. 2006; A. R. Woodruff & Sah 2007; Wolff et al. 2014) 
(Figure 3.2.5). Due to an incompatibility of immunostaining conditions for the Nlgn2 antibody 
and the PV and SOM antibodies, I cannot rule out the possibility that Nlgn2 may not be expressed 
in PV- and SOM-positive cells. However, the fact that the vast majority of gephyrin-positive 
synapses in BA also contain Nlgn2 would argue against this scenario. Alternatively, it is possible 
that differential compensation by other synaptic adhesion molecules may prevent altered activation 
of interneurons but not projection neurons, or that under my experimental conditions, acute 
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activation of these interneurons does not play a primary role in the anxiety circuitry. Regardless of 
the mechanism, my data support a model according to which reduced perisomatic inhibition at 
connections between PV-positive interneurons and CeM targeting projection neurons in BA of 
Nlgn2 KO mice results in specific overactivation of these projection neurons under anxiogenic 
conditions, consistent with the exaggerated behavioral anxiety response of Nlgn2 KO mice. 
 
The notion that synaptic adhesion proteins may function differently at distinct neurons and at 
distinct synapses, even on the same neuron, has lately received substantial attention. One recent 
study showed that deletion of Nlgn3 results in enhanced synaptic transmission at inhibitory 
connections between cholecystokinin (CCK)-positive interneurons and pyramidal cells in area 
CA1 of hippocampus, without affecting inhibitory connections formed by PV-positive 
interneurons onto the same pyramidal cells (Földy et al. 2013). Another study showed that deletion 
of Nlgn4 reduces inhibitory transmission onto excitatory neurons originating specifically 
from parvalbumin (PV)-positive interneurons in area CA1 in hippocampus (Hammer et al. 2015).  
These and other findings highlight the fact that the role of adhesion proteins in circuit function 
cannot be predicted from studies on dissociated cultures or by inference from other brain regions, 
but must be investigated in the context of specific behaviorally relevant neural circuits 
 
4.5.2 Consequences of IgSF9b Deletion on Neurons in CeM 
 
Consistent with my findings that point to a postsynaptic role of IgSF9b specifically in interneurons, 
PV- positive neurons show differential anxiety- associated cFOS induction in BA of IgSF9b KO 
mice (Figure 3.2.5). The most parsimonious explanation for a mechanism underlying higher cFOS 
expression of PV- positive neurons is a deficit in inhibitory tone onto these interneurons. Indeed, 
knockdown of IgSF9b in cell cultures reduces the frequency of mIPSCs in interneurons (Woo et 
al. 2013). The proposed deficit in inhibitory transmission in BA may appear contradictory to my 
findings of increased inhibitory transmission in CeM in IgSF9b KO mice. However, based on my 
observation, PV-positive cells are virtually absent from CeM. It is therefore plausible that IgSF9b 
regulates distinct aspects of inhibitory transmission in an interneuron subtype- specific manner. 
Consistent with this notion, deletion of IgSF9b does not lead to enhanced cFOS induction of SOM- 
positive interneurons in BA. Due to an incompatibility of staining conditions, I cannot assess the 
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possible molecular deficits specifically on PV interneurons, however the mechanism underlying 
reduced inhibitory tone in BA may involve an uncompensated reduction in 1 subunit of GABA 
receptors.    
 
It is surprising that enhanced inhibitory tone in BA does not result in reduced cFOS expression of 
excitatory projectors to CeM in IgSF9b KO mice. PV positive interneurons appear to have a 
complex role in regulation of projection neurons in BA during processing of aversive stimuli. For 
instance, PV-positive neurons reduced their firing during presentation of electric shock- paired 
stimulus and showed mixed responses to paw pinch (Bienvenu et al. 2012; Wolff et al. 2014). 
Here, I show that increased activation of PV-positive neurons does not suppress the excitatory 
anxiogenic output of BA during anxiety- related processing. Studying the exact contribution of 
PV- positive neurons to inhibition of anxiety- related excitability of projections neurons in BA, 
and the role of IgSF9b in regulation of PV- positive neurons may enhance our understanding of 
molecular mechanisms of anxiety.  
 
4.5.3 Combined Effect of Nlgn2 and IgSF9b Deletion on Neurons in BA  
 
The combined effect of IgSF9b and Nlgn2 deletion on activation of excitatory and inhibitory 
networks in BA of double KO mice recapitulates the effect of the single KO of each protein. 
Accordingly, both excitatory projection neurons, including those that target CeM, and inhibitory 
PV- positive interneurons, show high cFOS induction under anxiogenic conditions in double KO 
mice (Figures 3.2.5, 3.2.6). This finding suggests that the rescue of anxiety- related behavior in 
double KO mice does not arise from normalization of anxiogenic BA output, and therefore most 
probably occurs in downstream targets of BA, with CeM being the most obvious site of the rescue.  
 
Interestingly, the enhancement of PV- positive network is more robust in double KO than in 
IgSF9b KO mice. As PV- positive neurons receive excitatory connections from glutamatergic 
neurons in BA (Woodruff & Sah 2007), it is plausible that increased overall excitatory drive in 
Nlgn2 KO mice further enhances the IgSF9b- deletion conferred overactivation of  PV-positive 
neurons. The fact that this robust overactivation of PV-positive network is not accompanied by a 
suppression of glutamatergic neurons in double KO mice confirms that Nlgn2 deletion impairs 
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inhibitory transmission between PV-positive interneurons and glutamatergic neurons, and 
demonstrates that IgSF9b deletion does not rescue this major outcome of Nlgn2 deletion in BA. 
 
4.6 Consequences of Nlgn2 and IgSF9b Deletion on Anxiety- Associated Neural Activation 
of Basal and Centromedial Amygdala 
  
4.6.1 Anxiety- Associated cFOS Expression in Basal and Centromedial Amygdala 
 
While many of the amygdala nuclei are implicated in regulation of anxiety and fear behavior, most 
of the studies focused on the role of lateral amygdala (LA), BA, and lateral subdivision of central 
amygdala (CeL) in anxiety and fear related processing (Tovote et al. 2015; Janak & Tye 2015). 
The neural activity of these nuclei was linked to behavioral manifestations of conditioned fear 
during various stages of the fear-conditioning paradigm, with relatively few studies describing 
neural correlates of unconditioned anxiety- related behavior, such as the one measured during the 
open field test. Therefore, I characterized the anxiety- associated neural activity of LA, BA, CeL, 
and medial subdivision of central amygdala (CeM) in Nlgn2 KO, IgSF9b KO, double KO and WT 
mice, and additionally two posterior sub regions of BA in Nlgn2 KO and WT mice (Figures 3.1.4, 
3.2.4), by measuring the expression of neural activity marker cFOS (Schurr et al. 1985). Apart 
from BA and CeM, the rest of the assayed regions did not show differential anxiety- associated 
cFOS induction in any of the genotypes. This finding demonstrates that although LA and CeL are 
strongly involved in acquisition and storage of conditioned fear (LeDoux 2003), they may play a 
lesser role in mediation of anxiety-related behaviors. 
 
As might be expected from an anxiety-associated enhancement of BA-to-CeM projections in 
Nlgn2 KO mice, I observed a two-fold increase in cFOS expression in CeM in Nlgn2 KO mice, 
compared to WT mice (Figure 3.2.4). Strikingly, while Nlgn2 KO and double KO mice 
demonstrated similar overactivation of CeM-targeting excitatory projection neurons in BA, the 
anxiety- associated activation of CeM was completely rescued in double KO mice. Apart from the 
excitatory projections from BA, CeM receives inhibitory projections from CeL that were shown 
to regulate CeM activity during fear- related processing (Ciocchi et al. 2010). While I did not 
quantify the cFOS activation specifically of the neurons that project from CeL to CeM yet, this is 
an ongoing experiment that hopefully will help to determine whether the suppression of neural 
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activity of CeM in double KO mice may be a consequence of an increased inhibitory drive from 
CeL. Alternatively, as intrinsic inhibitory connections in the CeM exist (Jolkkonen & Pitkanen 
1998), the rescue of anxiety- associated activation of CeM may involve local increase in inhibitory 
transmission, such as identified in CeM of IgSF9b and double KO mice (Figure 3.2.20).    
 
4.6.2 Limitations of cFOS Assay  
 
While measuring cFOS expression provides an excellent quantitative estimate of neural activity 
during various behavioral states (Singewald et al. 2003; Knapska et al. 2007) and allows to 
simultaneously measure activity of several types of neurons, the cFOS assay has two major 
limitations, i.e. (1) the time-consuming nature of the current serial section-based methodology, 
and (2) the limited temporal resolution of the signal, which precludes direct correlation with 
behavioural responses. Below I discuss alternative approaches that I have implemented or initiated 
to overcome these limitations. 
 
4.6.2.1 Whole-brain functional imaging 
 
First, the cFOS assay is extremely time consuming, and due to its low throughput, neural activity 
of brain regions distal to amygdala, with the exception of medial prefrontal cortex, were not 
assessed in this study. However, additional brain regions such as BNST and ventral hippocampus 
are reciprocally interconnected with basal amygdala (Kim et al. 2013; Felix-Ortiz et al. 2013; 
Woodruff & Sah 2007) and may therefore contribute to the differential activation of BA in Nlgn2 
KO, IgSF9b KO and double KO mice. To fully characterize the mechanisms underlying anxiety- 
related phenotype of Nlgn2 KO mice and anxiety rescue in double KO mice, it would be necessary 
to assess the cFOS expression of the whole brain. 
 
It recently became possible to generate brain-wide cFOS expression maps using iDISCO, a novel 
optical clearing technique that allows for immunolabelling and rapid imaging of the whole brain  
using light sheet microscopy (Renier et al. 2016). Together with Dr. Krueger- Burg and Dr. Camin 
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Figure 4.2| cFOS and PV immunolabeling of whole mouse brain combined with optical clearing using 
iDISCO protocol. 
 
 
Dean, I implemented this technique and produced preliminary 3D image of amygdala and 
hippocampus labelled with cFOS and PV marker (Figure 4.2). Further application of iDISCO will 
help to fully map the brain regions that form the anxiety processing circuit in WT mice, as well as  
to characterize the role of Nlgn2 and IgSF9b in the regulation of distinct neuronal populations 
within these brain regions.  
 
4.6.2.2.  In vivo Recording of Neural Activity in Freely Behaving Mice 
 
The second limitation of cFOS assay is that it lacks the temporary resolution necessary to assess 
dynamic changes in neural activity during behavioral tasks, such as exploration of the open field. 
Therefore, I initiated a collaboration with Dr. Hugo Cruces-Solis to complement quantification of 
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cFOS expression with in vivo recordings of CeM while the mice explore the OF chamber. My 
primary motivation was to confirm that the rescue of neural activity in CeM, which I observed 
with the cFOS assay, correlates with the rescue of anxiety behavior. Additionally, I sought to 
characterize the contribution of the coordinated neural activity in CeM to the processing of 
aversive stimuli.   
 
4.6.3 Neural Activity of CeM During Exploration of the Open Field 
 
During exploration of the open field chamber, the neural activity of BA, including the firing of 
individual neurons and the local field potentials (LFPs) that correspond to coordinated firing of 
neuronal populations, increases as the mice transition into the center of the open field chamber 
(Likhtik et al. 2013). Therefore, neural activity of BA was postulated to differentially encode safety 
(the periphery of the open field) and danger (the center of the open field) (Stujenske et al. 2014; 
Likhtik et al. 2013). The danger- induced increase in neural firing of BA was proposed to activate 
CeM, the primary output region of the BA, which mediates autonomic and behavioral responses 
associated with anxiety (Krettek & Price 1978; Davis 1992; LeDoux et al. 1988). While 
characterizing the neural mechanisms underlying discrimination between safety and danger is one 
of the keys to understanding the pathophysiology of anxiety- related disorders, the neural 
activation of CeM during unconditioned behavioral manifestation of anxiety was never assessed.  
 
Together with Dr. Hugo Cruces- Solis, I measured the LFP of CeM in WT, Nlgn2 KO, IgSF9b 
KO and double KO mice during exploration of the open field chamber. Our findings confirm that 
IgSF9b deletion normalizes the otherwise robustly enhanced neural activity of CeM in Nlgn2 KO 
mice in the open field. Moreover, we identified a specific frequency range of oscillatory activity 
in CeM, i.e. the high -frequency range (70 -120 Hz), which strongly correlates with the extent of 
avoidance of the open field center. Accordingly, “anxious” Nlgn2 KO mice demonstrate an 
increase in oscillatory activity at 70-120 Hz during exploration of the open field center, which is 
rescued in the double KO mice. Finally, we show that activity of CeM increases specifically during 
transition into the center, indicating that similarly to BA, CeM can encode safety and danger 
signals.  
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As LFPs reflect the summary of excitatory and inhibitory synaptic inputs of a neural population 
(Mazzoni et al. 2012), it is possible that an increase in inhibitory synaptic transmission in CeM of 
double KO mice may contribute to the modulation of anxiety- related neural activity in CeM. Since 
GABAergic transmission in amygdala coordinates neural firing during behavioral responses to 
anxiogenic stimuli (Prager et al. 2016), proteins that regulate inhibitory synaptic function may play 
an important role in regulation of anxiety-associated neural activity. 
 
4.7 Conclusions: Implications for Molecular Mechanisms of Anxiety 
 
Anxiety is an essential part of normal behavioral responses to potentially threatening 
environmental stimuli. Nevertheless, excessive anxiety that translates into avoidance of non- 
threating situations, thus interfering with daily life, is a pathological condition with a lifetime 
prevalence of up to 28% (Kessler, Demler, et al. 2005). Anxiety is typically treated with 
benzodiazepines that enhance the overall GABAergic transmission (Macdonald & Barker 1978), 
but these drugs act non-specifically at the vast majority of inhibitory synapses in the central 
nervous system and hence cause a number of undesirable and potentially dangerous side effects. 
Therefore, there is a pressing need for detailed studies of the mechanisms underlying anxiety, with 
the goal of identifying novel therapeutic targets whose function is specific to brain regions, circuits 
and synaptic connections implicated in anxiety processing. 
 
A model organism is needed to study the neural underpinnings of anxiety. My work identifies 
Nlgn2 KO mice as an excellent mouse model of anxiety that recapitulates the key mechanisms 
underlying anxiety in humans, including increased activation of amygdala during processing of 
aversive stimuli (Etkin & Wager 2007), decreased GABAergic tone (Lydiard 2003) and excessive 
avoidance behavior (Bereza et al. 2009). Identification of Nlgn2 mutations in patients with 
schizophrenia and anxiety (Sun et al. 2011; Parente et al. 2016) further highlights the relevance of  
Nlgn2 to psychiatric conditions. Therefore, Nlgn2 KO mice offer construct validity and face 
validity and thus may provide insights into synaptic pathophysiology of anxiety, such as the 
findings presented in this work (summarized in Figure 4.4). 
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Figure 4.3| Viral delivery of GFP- Cre construct into basal amygdala. Scale bar, 20 m. 
 
Deletion of the novel synaptic protein IgSF9b rescues the enhanced anxiety phenotype of Nlgn2 
KO mice. While further studies are needed for the detailed description of IgSF9b function in 
anxiety in vivo, I identified that deletion of IgSF9b normalizes the increased anxiety-related 
processing in centromedial amygdala of Nlgn2 KO mice. This finding indicates that both Nlgn2 
and IgSF9b may play a crucial role in the modulation of anxiety behavior. Experiments to establish 
causality between IgSF9b deletion and the rescue of anxiety in Nlgn2 KO mice are underway. 
Virus-mediated delivery (Figure 4.3) of IgSF9b shRNA knockdown construct into basal and/or 
centromedial amygdala will address two important questions. First, it will determine whether 
IgSF9b acts to rescue anxiety in a specific brain region. Second, as IgSF9b knock down will take 
place in adult animals, it will determine whether anxiety-conferring aberrant neural activity can be 
corrected at post developmental stages.  
 
I demonstrate here that both Nlgn2 and IgSF9b act at specific subpopulations of inhibitory 
synapses. Deletion of Nlgn2 affects synaptic transmission at perisomatic synapses surrounding 
excitatory neurons in BA, while deletion of IgSF9b affects perisomatic synapses onto inhibitory 
interneurons in CeM.  By identifying proteins that regulate transmission at particular synaptic 
connections which are especially relevant to the generation of pathological anxiety behaviors, it 
may be possible to develop improved therapeutic strategies that target these synapses more 
specifically and are better suited to the treatment of at least a subset of anxiety disorders. Further 
experiments aimed to link Nlgn2 and IgSF9b to behavioral phenotypes related to psychiatric 
disorders may provide essential insights into underlying molecular mechanisms and potential drug 
targets for the treatment of these disorders. 
DISCUSSION 
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Figure 4.4| Summary of the effects of Nlgn2 deletion and IgSF9b deletion on anxiety- processing 
circuit.
Synaptic
Proteins
• Reduced perisomatic gephyrin in BA
• Reduced perisomatic GABAr1 subunit in BA
Neuronal 
Networks
• Reduced inhibitory transmission onto excitatory neurons in BA
• Enhanced activation of excitatory neurons that project to CeM
• Enhanced inhibitory transmission onto inhibitory neurons in CeM
Amygdala
Regions
• Enhanced neural activation of BA
• Enhanced neural activation of CeM
• Rescue of neural activation of CeM
Effect of Nlgn2 deletion
Effect of IgSF9b deletion in Nlgn2 KO mice
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